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Modulation of the sensitivity of nociceptive neurones by cannabinoids and SNSRs 
Stuart Andrew Honan 
The sensation of pain is evoked when the body experiences noxious stimuli, and such 
stimuli are detected by specialised primary sensory neurones called nociceptors. Modulation 
of the sensitivity of these nociceptors occurs physiologically when they are exposed to 
inflammatory exudates. A fuller understanding of the means by which these neurones are 
modulated will provide relevant information for the rational development of analgesics. 
The receptors for cannabinoids, the active ingredients of cannabis, have been found in some 
, primary sensory neurones. Given the known ability of these receptors to inhibit adenylate 
cyclase, the activation of which leads to the sensitisation of nociceptors, calcium imaging was 
used to assess if the application of a synthetic cannabinoid agonist (WIN 55,212-2) would 
attenuate the responsiveness of nociceptors in vitro. After examining this in both a non-
sensitised model and a model of sensitisation employing prostaglandin E2 (PGE2), it was 
evident that, in the in vitro model employed, the method of activating cannabinoid receptors 
did not result in any significant effect. 
Another family of G-protein coupled receptors found exclusively in sensory neurones 
(Sensory Neurone Specific Receptors or SNSRs) were then examined to see if the application 
of their agonist, bovine adrenal medulla peptide (BAM (8-22)), modulated the response of 
nociceptors in vitro. A sub-population of neurones was seen to sensitise in their response to 
capsaicin after exposure to BAM (8-22). A selection of kinase inhibitors was then employed 
to elucidate the intracellular pathway involved in this sensitisation, and protein kinase C 
(PKC) was found to play a significant role. The specific PKC-isoform involved, however, 
was not able to be elucidated using immunocytochemistry. Whole cell patch clamp studies 
both confirmed the findings from the calcium imaging study, and established that the transient 
receptor potential vanilloid receptor itself was sensitised by the application of BAM (8-22). 
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1.1 Pain: A general overview 
Pain is "an unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage" (IASP Task Force on Taxonomy, 
1994). It is an important sense that helps to prevent or limit damage to the body, and thus 
performs an essential role in survival. As a sensation experienced by all of us it has been of 
interest to humanity for centuries whether through means to alleviate it or through attempts to 
describe the mechanism by which noxious stimuli result in it. An attempt by Rene Descartes 
to describe this mechanism in 1644 went as follows: "If for example the fire ... comes near the 
foot ... , the minute particles of this fire, which as you know move with great velocity, have the 
power to set in motion the spot of the skin of the foot which they touch, and by this means 
pulling on the delicate thread ... they open up at the same instant the pore ... against which the 
delicate thread ends, just as by pulling against one end of a rope one makes to strike at the 
same instant a bell which hangs at the other end". This description relates the communication 
of a noxious stimulus via an internal physiological means to the brain, in which the striking of 
the bell can be correlated with the emotional sensation of pain. Nowadays, we are aware of 
the specialised sensory nerves that detect and transduce noxious stimuli. However, it was not 
until the late 19th Century that theories providing the formation for our current understanding 
of pain began to take shape. 
The specificity theory of sensation which states that a given sense organ will respond to the 
stimuli it is adapted for, activity in a given nerve will always give rise to the same sensation, 
and that different parts of the central nervous system are responsible for specific sensations, 
was originated by Johannes Muller and Charles Bell (1842). Von Frey (1894) applied this 
theory to pain by suggesting that somatic sensory receptors existed for it thus leading to it 
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being established as a sensory experience. The concept of peripheral receptors for painful 
stimuli was readily accepted by Sherrington and Head who noted that in the cornea, where 
only the sensation of pain can be evoked, there is just one type of nerve-ending (more recently 
examined by Belmonte et al. (1991)). This led Sherrington to propose in 1906 that the 
detection of noxious stimuli be termed nociception, and that sensory neurones specifically 
sensitive to noxious stimuli be termed nociceptors. These nerves make connections with the 
dorsal horn of the spinal cord, from which subsets of neurones transmit signals to higher brain 
centres, including the reticular formation, thalamus and the cerebral cortex, in which 
conscious recognition of pain occurs (Basbaum and Jessell, 2000). 
For pain to be perceived, Tillman et al. (1995) have shown that a certain discharge 
frequency must be reached in the nociceptive neurones. The amount of pain perceived for a 
given stimulus, however, is also dependent on physiological state. In the presence of 
inflammation both allodynia (the perception of pain due to a normally innocuous stimulus) 
and hyperalgesia (an increased sensation of pain for a given noxious stimulus) occur (Cervero 
and Laird, 1996). The role of hyperalgesia is to prevent further injury to an already damaged 
area of tissue. Hyperalgesia localised to the site of injury is termed primary hyperalgesia, 
whereas hyperalgesia in the surrounding uninjured area is termed secondary hyperalgesia 
(Lewis, 1935, 1942). Primary hyperalgesia is believed to be as a result of the sensitisation of 
nociceptors (Meyer and Campbell 1981, La Motte et al. 1982). In this respect nociceptors 
show a fundamental difference from other sensory receptors. Nociceptors, as with other 
sensory receptors, demonstrate adaptation- in this case to noxious stimuli that fail to produce 
actual tissue damage (Cesare and McNaughton, 1997). However, unlike other sensory 
receptors, they demonstrate the ability to be sensitised by mediators released when tissue is 
damaged. Inflammatory mediators include bradykinin (Beck and Handwerker, 1974), 
prostaglandins (Taiwo et al., 1987), 5-hydroxytryptamine (5-HT), histamine (Coelho et al., 
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1998), and nerve growth factor (NGF) (Amann et al., 1996). Increased activity in the primary 
afferent neurone also contributes to inflammation (Lembeck and Holzer, 1979) via a 
phenomenon known as neurogenic inflammation in which neuropeptides such as calcitonin 
gene related peptide (CGRP) and substance P are released (Lynn, 1996) thus providing a 
positive feedback on sensitisation from the nociceptive nerve terminals themselves. 
Secondary hyperalgesia on the other hand is believed to be as a result of an augmentation of 
the response of spinal pain-signalling neurones to input from low-threshold mechanoreceptors 
(central sensitization) (Woolf, 1983). 
1.2 Nociceptive neurones 
Classification 
In general, fine nerve fibres originating from medium- and small-diameter cell bodies in 
dorsal root ganglia (DRGs) are implicated in nociception- specifically thinly myelinated A8 
fibres, and slower conducting unmyelinated C fibres. The Ao fibres are generally involved in 
mechanical nociception (Burgess and Perl, 1967) but some have been reported also to be 
excited by noxious heat (Iggo and Ogawa, 1971 ), whereas the C fibres are polymodal-
responding to strong mechanical stimuli, noxious heat and irritant chemicals (Bessou and 
Perl, 1969). A-fibres have been shown to mediate the fast, pricking quality of pain whereas C 
fibres mediate the slower, burning quality of pain (for review see Stucky et al., 2001). C 
fibres comprise around 70% of all nociceptors and histochemical studies of adult DRGs have 
shown that they can be split into two groups: a peptidergic group, containing substance P, 
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CORP and expressing the Trk:A receptor for NGF (Averill et al., 1995); and a non-peptidergic 
group that express P2X3 receptors (Bennet et al., 1998) and can be labelled selectively with 
the isolectin B4 (IB4). In addition, there are some nociceptors-'silent' nociceptors-that 
only respond when sensitised by tissue injury (Schmidt et al., 1995). 
Excitation 
In recent years the molecular basis underlying the transduction of noxious stimuli has been 
advanced as a result of the use of isolated sensory neurones in culture (Baccaglini and Hogan, 
1983; Cesare and McNaughton, 1996) and the cloning of specific nociceptive genes (Akopian 
et al., 1996). In general, a range of receptors for different noxious stimuli present in 
nociceptive neurones results in the polymodal nature of nociceptors. These receptors include: 
ATP-gated channels composed of a nociceptor specific P2X3 subunit (Chen et al., 1995; 
Lewis et al., 1995; Cockayne et al., 2000); 5HT2 (Todorovic and Anderson 1990) and 5HT3 
receptors (Robertson and Bevan, 1991; Fozard, 1984); acid sensing ion channels (Waldmann 
et al., 1997; Waldmann and Lazdunski, 1998); H1 receptors for histamine (Tani et al., 1990); 
the transient receptor potential vanilloid 1 cation channel (TRPVl; formerly known as the 
vanilloid receptor) involved in detecting capsaicin and noxious heat (Caterina et al., 1997); 
and B2 receptors which detect the production of bradykinin and thus the release of proteolytic 
enzymes from damaged cells (Burgess et al., 1989; Mizumura et al., 1990). Whereas some of 
the transducers are ligand-gated ion channels, H1, 5HT2 and B2 are G-protein coupled 
receptors and thus bring about their effects indirectly. B2 receptors, via the production of 1,2-
diacylglycerol (DAG) and activation of protein kinase C (PKC), depolarise neurones by 
opening a non-selective cation channel (Burgess et al. , 1989; McGehee and Oxford, 1991 ). 
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The initial identification of this ion channel was followed by the identification of other ion 
channels which were also members of the TRP ion channel family and were found to cover the 
range of thermosensation from cold to hot (for review see Patapoutian et al., 2003) as the 
thermosensation of different sub-populations of DRG neurones was identified. Patapoutian et al. 
(2003) dubbed these channels thermoTRPs as temperature alone could activate them. After 
TRPVI, the TRPV2 channel, which responds to temperatures greater than 52°C, was the next to 
be discovered (Caterina et al., 1999). McKemy et al. (2002) cloned a TRP ion channel activated 
by menthol and cool (with a threshold of approximately 26°C). The range of TRP ion channels, 
as noted above, covers the range of temperatures from cold to hot: ANKTMI (:SI 7°C), TRPM8 
(::S25°C), TRPV4 (-27-42°C), TRPV3 (>33°C), TRPVI (~42°C), and TRPV2 (~52°.C) (See table 
I in Patapoutian et al., 2003). The expression of these ion channels is not necessarily in mutually 
exclusive sub-populations of DRG neurones as is seen by the co-expression of TRPVl with 
ANKTMI (Story et al., 2003). Although these ion channels share the characteristic in that they 
can be activated by the temperature alone, other characteristics differ e.g. in their response to 
repeated challenges: TRPV3 shows marked sensitisation (Peier et al., 2002; Xu et al., 2002) 
whereas TRPV4 shows desensitisation (Guler et al., 2002). TRPVI, as well as showing slight 
sensitisation to repeated challenges (Jordt and Julius, 2002), can also be activated by a range of 
stimuli. 
5HT2 receptors depolarise dorsal root ganglion (DRG) neurones by reducing a resting K+ 
conductance (Todorovic and Anderson, 1990). Thus noxious stimuli are transduced into a net 
inward current which can result in the depolarisation of the nociceptors, and formation of an 
action potential. 
Of the transducers of noxious stimuli mentioned above, the ligand-gated ion channel 
TRPVI, which was cloned by Caterina et al. (1997), is one of the best understood.* It is 
activated by capsaicin (Caterina et al., 1997), the pungent ingredient of chilli peppers, the 
endocannabinoid anandamide (Zygmunt et al., 1999; Smart et al., 2000), and noxious 
temperatures greater than 43°C (Torninaga et al., 1998), the last matching the threshold of 
heat-evoked electrophysiological responses in cultured sensory neurones (Cesare and 
McNaughton, 1996). Both the capsaicin-evoked responses (Caterina et al., 1997; Tominaga 
et al., 1998) and the heat-activated currents (Tominaga et al., 1998) can be modulated by 
protons. In mice lacking this receptor there are no responses to capsaicin and detection of 
noxious heat is impaired (Caterina et al., 2000). As capsaicin sensitivity is a major trait of a 
large sub..:population of nociceptive neurones, monitoring the activity of TRPVl provides a 
suitable means of monitoring the responsiveness of nociceptive neurones. Indeed, double-
labelling studies have shown that TRPVl is expressed by both unmyelinated peptidergic and 
nonpeptidergic neurones in DRG (Tominaga et al., 1998; Michael and Priestley, 1999). 
Michael and Priestley (1999) also found a population ofTRPVl positive neurones that did not 
belong to either of these groups. These very small DRG neurones, however, were found to 
represent just over 1 % of the cells examined. 
A range of ion channels, which can be subject to modulation, are involved in the excitatory 
state of nociceptive neurones. As in all neurones, voltage-gated . sodium channels play an 
important role in excitability and action potential generation. Some DRG neurones, as well as 
expressing a tetrodotoxin-sensitive sodium current, also express a tetrodotoxin-resistant 
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(TTX-R) sodium current which is especially predominant in the capsaicin-sensitive 
subpopulation (Arbuckle and Docherty, 1995). Two ion channels have been found to underlie 
this TT.X-R sodium current: Navl.8 (Akopian et al., 1999), and Navl.9 (Tate et al., 1998; 
Cummins et al., 1999). These ion channels have been found to be important in regulating the 
excitability of DRG neurones (Cummins et al., 1999) to noxious stimuli (Akopian et al., 
1999), and in inflammatory hyperalgesia (Khasar et al., 1998; Akopian et al., 1999). 
IA (a type of K+ current) is one of the main factors regulating the maximum firing frequency 
of neurones (Connor and Stevens, 1971), and is expressed by small diameter capsaicin-
sensitive neurones (Cardenas et al., 1995). IK(Ca) 'small' conductance (SK) channels are 
, responsible for a very prolonged afterhyperpolarisation (AHP) seen in a subpopulation of C 
neurones (Akins and McCleskey, 1993) which has a major influence on the ability of a 
neurone to fire repetitively in response to a maintained depolarisation (Weinreich and 
Wonderlin, 1987). This slow AHP is susceptible to inhibition by inflammatory mediators 
such as prostaglandins (Weinreich and Wonderlin, 1987) which results in the promotion of 
repetitive firing. Ih is a non-selective voltage-dependent channel activated by 
hyperpolarisation and is found in sensory neurones. Its potentiation may lead to more rapid 
repolarisation after an action potential and to facilitation of repetitive firing (Ingram and 
Williams, 1996). A range of voltage-gated calcium channels are found in sensory neurones, 
of which N- and P/Q-type channels in particular are important because of their role in 
mediating transmitter release (Reuter 1996; Santicioli et al., 1992). 
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Sensitisation 
As mentioned above sensitisation of nociceptive neurones underlies primary hyperalgesia. 
Toe principal situation in which this occurs is inflammation. Components of the 
"inflammatory soup" (which are chemical mediators released from primary sensory neurones 
and non-neuronal cells such as mast cells and neutrophils following tissue injury, Julius and 
Basbaum, 2001) can either sensitise nociceptors by directly interacting with ion channels or 
by mediating their effects indirectly through second-messenger signalling cascades. As 
discussed above, protons can directly modulate the responsiveness of TRPVl. 5HT 
(Cardenas et al., 2001), tumour necrosis factor a (TNFa) (Junger and Sorkin, 2000), NGF 
(Shu and Mendell, 1999), histamine (Mizumura et al., 1994), prostaglandins (England et al., 
1996) and bradykinin (Burgess et al., 1989) all modulate the sensitivity of nociceptors 
through intracellular signalling mechanisms. One of the intracellular signalling pathways 
utilised involves the activation of PKC- this is the case with bradykinin (Burgess et al., 
1989) where the activation of PKC augments both the heat-evoked current in cultured DRG 
neurones via the epsilon isoform (Cesare and McNaughton, 1996; Cesare et al., 1999a) and 
enhances the response to capsaicin in these neurones (V ellani et al., 2001 ). As reviewed by 
Jaken (1996) there are at least 12 isoforms of PKC, which can be divided into 3 groups: 
conventional isoforms which are activated by calcium and phorbol esters (a, ~1, ~n and y); 
novel isoforms which are activated by phorbol esters but are calcium independent ((), c, 8, TJ 
and µ); and atypical isoforms (~, 'A, and i-) which are calcium-independent and phorbol ester-
insensitive. Five isoforms were found by Cesare et al. (1999a) in the cultured neonatal rat 
DRG neurones: PKC- ~,, ~n, (), c, and ~- In embryonic (Olah et al., 2002) and adult (Ma et al., 
2001) rat DRG neurones, however, the isoform PKC-a was also found. 
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The other major intracellular signalling pathway involved in the sensitisation of nociceptive 
neurones is the cyclic 3 ',5 '-adenosine monophosphate/protein kinase A ( cAMP /PKA) 
pathway. Prostaglandins (Hamprecht and Schultz 1973) and 5HT (Neufeld et al. , 1982) have 
both been shown to elevate intracellular cAMP in numerous tissues, and analogues of cAMP 
have been shown to produce hyperalgesia (Taiwo et al., 1989). 
Prostaglandin E2 (PGE2) as an inducer of primary hyperalgesia 
Prostaglandins are known to be potent mediators of inflammation, and in tissues exhibiting 
an inflammatory response prostaglandins are elevated. The predominant prostaglandin 
involved in inflammation is PGE2 (Willis, 1969; Piper and Vane, 1969) and one of its effects 
is the generation of hyperalgesia, which underlies the pain of inflammation. This has been 
established in a range of in vivo and in situ studies, including those showing that PGE2 
injection both increases the sensitivity of nociceptive neurones to noxious stimuli, including 
capsaicin, · and recruits fibres that were insensitive before to the same noxious stimulus 
(Mense, 1981 ; Yanagisawa et al., 1986; Taiwo et al., 1989; Taiwo and Levine, 1991). The 
effect has been confirmed in cultured DRG neurones to be via a direct action which enhances 
their excitability and recruits neurones that did not respond to noxious stimuli before 
(Baccaglini and Hogan, 1983; Nicol and Cui, 1994; Cui and Nicol, 1995; Stucky et al., 1996; 
Gold et al., 1996a). The clinical importance of prostaglandin hyperalgesia is emphasised by 
the fact that the analgesic action of the potent non-steroidal anti-inflammatory drugs involves 
inhibition of the cyclo-oxygenase (COX) pathway (Smith & Willis, 1971) and thus inhibition 
of prostaglandin synthesis at peripheral sites of inflammation (Ferreira 1972). The PGE2 
evoked hyperalgesia has been shown to involve the activation of the cAMP/PKA pathway 
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(Taiwo et al., 1989; Pitchford and Levine, 1991; Taiwo and Levine, 1991; Cui and Nicol, 
1995) via the PGE2 receptors EP3C and EP4 (Southall and Vasko, 2001). Recently, the 
molecular nature of this PGE2 sensitisation has been elucidated. Gold et al. (1996a) and 
England et al. (1996) both showed that PGE2 caused a modulation of the TTX-R sodium 
current present in nociceptive neurones. This current was both increased in magnitude, and 
its activation threshold was shifted in a hyperpolarised direction resulting in a general increase 
in excitability. Lopshire and Nicol (1998) have also shown that PGE2 affects the capsaicin 
mediated current by increasing the activity of the TRPVl ion channel (Caterina et al., 1997). 
PGE2 can also enhance the excitability of DRG neurones by inhibiting voltage-gated 
potassium currents (England et al., 1996; Nicol et al., 1997) and enhancing the Ih current 
(Ingram & Williams, 1996). 
Given our current knowledge of the molecular basis of nociception and hyperalgesia, it is 
worth examining how it would be possible to attenuate these phenomena. One manner would 
be to use physiological 'antagonism' to attenuate the sensitisation of nociceptors and/or 
moderate their response. Recently the possibility of using a cannabinoid receptor agonist for 
this purpose has come to light. 
1.3 Cannabinoid Receptors 
Throughout history cannabis has been used in various cultures for its analgesic actions 
(Abel, 1979~a fact that was brought to the attention of the Western medical establishment in 
the 19th Century (O'Shaugnessy, 1842; Reynolds, 1890). This analgesic action, as well as the 
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other neurobehavioural and physiological effects of cannabis, is mediated by the active 
components known as cannabinoids, of which !::..9-tetrahydrocannabinol (1::..9 -THC) is the 
principal member (Gaoni and Mechoulam, 1964). The means by which cannabinoids brought 
about their effects in the body was originally· believed to be by a cell membrane perturbing 
action (Lawrence and Gill, 1975; Hillard et al., 1985). A series of reports, however, 
suggested the involvement of a G protein-coupled receptor, after the identification in brain 
and neural cell lines of a high affinity, stereoselective site for cannabinoids which mediated 
the inhibition of adenylate cyclase in a pertussis toxin-sensitive manner (Howlett and 
Fleming, 1984; Howlett, 1985; Howlett et al., 1986; Devane et al., 1988). These reports were 
soon followed by the cloning of the first cannabinoid receptor (CB1) (Matsuda et al., 1990) 
(mainly associated with neuronal tissue and the central nervous system (CNS)), and 
subsequently by the cloning of a second cannabinoid receptor (CB2) which is mainly 
associated with non-neuronal tissue such as the immune system (Munro et al., 1993). 
Recently, putative endogenous cannabinoids which are derivatives of arachidonic acid have 
been identified: arachidonyl ethanolamide (anandamide; AEA) (Devane et al., 1992), 2-
arachidonylglycerol (Mechoulam et al., 1995; Sugiura et al., 1995), 2-arachidonyl glyceryl 
ether (Hanus et al., 2001) and palmitoylethanolamide (PEA) (Facci et al., 1995). 
These discoveries resulted in the proposal that the activation of cannabinoid receptors in the 
CNS by either exogenous or endogenous cannabinoids produces antinociception (Y aksh, 
1981; Lichtman and Martin, 1991; Martin et al., 1993; Smith et al., 1994; Meng et al., 1998), 
and that endogenous cannabinoids have a role in tonically regulating pain thresholds in the 
CNS (Meng et al., 1998). Recently, however, much interest has surrounded reports that 
cannabinoids can affect nociceptive processing by interacting with receptors in the periphery; 
an effect that is appealing when developing prospective therapies given the potential to 
separate the beneficial actions from the undesirable, psychoactive effects of cannabinoids 
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acting upon receptors in the brain (Degenhardt and Hall, 2002). These studies, discussed 
below, have ranged from in viva behavioural experiments to localisation studies utilising 
radioligand binding, in situ hybridisation, and immunohistochemistry, to studies utilising 
cultured DRG neurones. Furthermore, although studies showing antinociceptive effects of 
cannabinoids may have physiological interest, antihyperalgesic effects are much more 
desirable if a future pharmaceutical is desired given the importance of inflammatory pain in 
clinical settings ( e.g. postoperative pain). Such antihyperalgesic effects have been seen in 
behavioural studies on the peripheral actions of cannabinoids, in the context of various 
models of sensitisation. 
In viva studies 
The carrageenan model of hyperalgesia, whereby the injection of this seaweed extract 
results in a time-dependent inflammation and subsequent thermal hyperalgesia, is a useful 
model for assessing anti-hyperalgesic and anti-inflammatory agents (Sammons et al., 2000). 
The hyperalgesia produced by both peripheral mechanisms involving primary nociceptors and 
central mechanisms involving spinal cord neurones (Richardson et al., 1998a; Richardson et 
al., 1998b) was seen to be prevented in a dose-dependent manner by intraplantar and 
intrathecal administration of anandamide (an endogenous agonist of CB 1 receptors (Devane et 
al., 1992)). The action of the endocannabinoid in both cases was linked, via CB1 receptors, to 
an inhibition of the release of CGRP, an inflammatory neuropeptide released from primary 
afferent fibres- from central terminals with respect to the intrathecal administration, and from 
peripheral terminals with respect to the intraplantar administration. Interestingly, intrathecal 
administration of the same dose of anandamide in normal animals was not seen to have any 
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antinociceptive effect, thus suggesting that the attenuation acted on a factor involved in 
hyperalgesia but not normal nociception (Richardson et al., 1998b ). In the experiments 
utilising intrathecal administration, the antihyperalgesic effect was probably as a result of the 
prevention of afferent barrage. Afferent barrage is the high frequency stimulation of primary 
afferents that results in the sensitisation of dorsal horn neurones and thus secondary 
hyperalgesia. Anandamide, by acting presynaptically on the central terminals of primary 
afferents, could prevent this by inhibiting neuropeptide release. This was suggested to be 
either via the inhibition of calcium channels (Mackie and Hille, 1992; Caulfield and Brown, 
1992) which would prevent exocytosis of the neuropeptides which function as transmitters at 
the dorsal horn, or by the opening of potassium channels (Deadwyler et al., 1993; Henry and 
Chavkin, 1995) which would stabilise the pre-synaptic membrane potential. 
In the experiments utilising intraplantar injection, the inhibition of hyperalgesia could be 
due to the prevention of neurogenic inflammation. This would likely be by the inhibition of 
neuropeptide release from peripheral terminals because of the location of the drug. 
Furthermore, in these experiments, anandamide was shown to be able to attenuate the 
maintenance of hyperalgesia. This possibly suggests an involvement of CB1 receptors, 
expressed on peripheral nociceptors, in attenuating the sensitising effects of inflammatory 
mediators that are present after the induction of neurogenic inflammation. Thus, this 
activation of CB1 receptors on peripheral terminals is probably inhibiting primary 
hyperalgesia directly, and secondary hyperalgesia indirectly. 
The formalin model is another means of inducing hyperalgesia that has been used to 
elucidate how the activation of cannabinoid receptors interact with inflammatory 
hyperalgesia. There are two phases to the formalin model: the first phase involves the acute 
activation of nociceptive C fibres in response to the injection process itself, whereas the 
second phase involves the response to the sensitisation of the nociceptive pathway both at the 
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level of the primary afferent (peripheral sensitisation) and the level of the dorsal horn ( central 
sensitisation) (Tjolsen et al., 1992). Both Jaggar et al. (1998) and Calignano et al. (1998) 
found that the activation of CB1 receptors or CB2 receptors by a range of cannabinoid 
agonists, including anandamide, PEA, WIN 55,212-2 and HU2IO, attenuated the second 
phase of the behavioural responses to formalin injection thus suggesting an antihyperalgesic 
role mediated by the activation of these receptors. Although the actions of PEA via CB2 
receptors is most likely a peripheral mechanism given the location of these receptors on non-
neural tissue, the actions of CB1 agonists could be in either a central or peripheral location. 
Jaggar et al. (1998) used an intraperitoneal route of administration for anandamide and so the 
,antihyperalgesic effect of anandamide could not be localised to either a central or peripheral 
effect. Calignano et al. (1998), however, showed that a peripherally active dose of 
anandamide given by the intraplantar route was much less effective when given by a systemic 
route (e.g. intravenously) and thus established a peripheral mechanism of action. Therefore at 
least some of the effect reported by Jaggar et al. (1998) may have been mediated by 
cannabinoid receptors in the periphery. Furthermore, Nackley et al. (2003) found that 
intraplantar injection of WIN 55,212-2 attenuated inflammatory nociception via peripheral 
cannabinoid receptors. Given the findings of the studies using carageenan injection, 
discussed above, anandamide may be affecting hyperalgesia by inhibiting neurogenic 
inflammation, which would prevent peripheral sensitisation and primary afferent barrage. A 
role, however, for a direct modulatory effect on the sensitisation of nociceptive neurones by 
inflammatory mediators cannot be ruled out. 
A point of disagreement between two of the papers is the means by which PEA brings about 
its antihyperalgesic effect. Jaggar et al. (1998) suggest that PEA activates CB2 receptors on 
mast cells to inhibit the release of inflammatory mediators (Facci et al., 1995; Mazzari et al., 
1996) which otherwise could be expected to sensitise primary afferents. Calignano et al. 
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(1998), . however, discounted this possibility as they failed to detect any effect on 
inflammatory oedema that overlapped with the effect on hyperalgesia. It is likely that the 
fonner scenario holds some truth, but with the recent potential detection of CB2-like 
immunoreactivity on cultured DRG neurones (Ross et al., 2001), a direct effect on peripheral 
· afferents cannot now be ruled out. 
Finally, another in vivo model of hyperalgesia uses capsaicin (the pungent extract of chilli 
peppers). Exposure of nociceptive neurones to capsaicin initially leads to the excitation of the 
neurone (resulting in the perception of pain and the local release of inflammatory mediators 
such as substance P and CGRP) (Winter et al., 1995). This is followed by the development of 
both primary and secondary hyperalgesia (Baumann et al., 1991; LaMotte et al., 1992). 
Indeed, the exposure of human skin to capsaicin has been reported to result in hyperalgesia 
(Simone et al., 1989). WIN 55,212-2 has been seen both to inhibit dose-dependently the 
nocifensive response produced by an injection of capsaicin, and to also block the development 
of mechanical and thermal hyperalgesia (Li et al., 1999; Johanek et al., 2001). Notably, no 
effect on basal withdrawal latencies to thermal stimuli was seen, thus reinforcing the theory 
that WIN 55,212-2 was antihyperalgesic and not antinociceptive. Because in this study the 
route of administration was intravenous, it is not possible to specify if the action was centrally.. 
or peripherally-mediated. A peripheral site of action is, however, possible as the prevention 
of the release of inflammatory neuropeptides from the nociceptors (as discussed above) would 
both limit inflammatory sensitisation of the primary afferent fibres themselves (peripheral 
sensitisation), and aid in the reduction of primary afferent barrage, resulting in central 
sensitisation. Indeed, Ko and Woods (1999) also used a capsaicin model of hyperalgesia and 
found that /19 -THC peripherally inhibited, via CB1 receptors, the development of thermal 
allodynia following the injection of capsaicin. As with the study by Li et al. (1999), no 
antinociceptive effect to a noxious thermal stimulus was seen in the absence of capsaicin, thus 
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reinforcing the antihyperalgesic nature of the effect of the cannabinoid. More recent reports, 
however, have shown that the activation of peripheral cannabinoid receptors can result in 
antinociception: Dogrul et al. (2003) found that WIN 55,212-2 applied topically to the tail of 
a mouse can have an antinociceptive effect in the tail-flick test via CB1 receptors; Malan et al. 
(200 I) found that the activation of CB2 receptors had an antinociceptive action with respect to 
thermal stimuli; and Sokal et al. (2003) found that anandamide inhibited mechanically-evoked 
responses under inflammatory conditions via CB2 receptors. 
Various in vivo behavioural models have therefore shown that the activation of cannabinoid 
receptors in the periphery has an antihyperalgesic effect, as well as possibly an 
antinociceptive effect. An antihyperalgesic effect can be as a result of an inhibition of the 
release of inflammatory mediators as well as an attenuation of their effect on nociceptive 
neurones. Quartilho et al. (2003) found that the activation of peripheral CB2 receptors 
inhibited inflammation and the associated hyperalgesia- a result borne out by Nackley et al. 
(2003) in a carrageenan model of inflammation. The mechanisms underlying the anti-
inflammatory actions of endocannabinoids include attenuation of NGF-induced mast cell 
degranulation and of neutrophil accumulation (Rice et al., 2002), as well as the attenuation of 
NO release by astrocytes (Molina-Holgado et al., 2002), on which CB1-like immunoreactivity 
has been detected (Salio et al., 2002). 
Because of the nature of behavioural studies it is difficult to ascertain all of the possible 
effects of cannabinoids on the neurones themselves in this respect. Such a problem would be 
solved by in vitro studies, but first it is worth discussing reports confirming the localisation of 
cannabinoid receptors to nociceptive neurones. 
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Localisation studies 
Although the in viva behavioural studies strongly suggest that cannabinoids have a 
peripheral site of action with respect to the modulation of nociceptive neurones, and that 
actions via both CB1 and CB2 receptors are important, they do not confirm the precise 
location of the receptors in the periphery that are important for these actions. A range of 
localisation studies has been carried out to ascertain if primary afferent fibres involved in 
nociception express cannabinoid receptors, and to see which subpopulations of nociceptors 
are important. Richardson et al. (1998a), utilising radioligand binding studies, noted that 
·cannabinoid receptors could be expressed on primary afferent fibres. Furthermore, the actions 
of cannabinoids in inhibiting the release of neuropeptides from the central terminals of 
primary afferents (Richardson et al., 1998a) would suggest their localisation on these primary 
afferents. Indeed, Hohmann and Herkenham (1998) did find a reliable suppression of 
cannabinoid receptor binding sites following long term neonatal capsaicin treatment (known 
to destroy nociceptive primary afferents ), providing an anatomical basis for this action. The 
suppression of binding, however, was only moderate suggesting that the majority of 
cannabinoid receptors in the superficial dorsal horn did not lie presynaptically on the central 
terminals of these capsaicin sensitive nociceptors. A further in vitro receptor binding study 
utilising dorsal rhizotomy demonstrated that 50% of cannabinoid binding sites at the level of 
the spinal cord reside on the central terminals of primary afferents (Hohmann et al., 1999). 
To ascertain on which neuronal subpopulations of DRGs cannabinoid receptors are located, a 
double-label in situ hybridisation study was carried out (Hohmann and Herkenham, 1999b ). 
CB1 messenger RNA (mRNA) was detected in DRG neurones thus showing that DRG 
neurones can express cannabinoid receptors. Furthermore, some overlap with neurones 
expressing neuropeptide markers indicative of nociceptive neurones (i.e. CGRP and substance 
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P) was demonstrated, again providing evidence for an anatomical substrate underlying the 
cannabinoid-mediated inhibition of CGRP release from both peripheral and central terminals 
of nociceptive neurones (Richardson et al., 1998a; Richardson et al., 1998b). Also CB1 
mRNA was restricted to 10-15% of DRG neurones, the majority of which did not express 
these peptide markers and were of a large diameter (suggesting a localisation to AJ3 and A3 
fibres). A further study using in vitro receptor binding and sciatic nerve ligation demonstrated 
that these cannabinoid binding sites did undergo transport to the peripheral terminals of the 
primary afferent nerves (Hohmann and Herkenham, 1999a). This study also found no 
evidence that CB2 receptor mRNA was synthesised by DRG neurones. 
Despite these studies, Farquhar-Smith et al. (2000), utilising an antibody raised against part 
of the C-terminal of the CB1 receptor, found in the dorsal horn tha~ whereas there was 
localisation in the same lamina of CB1-like immunopositive neurones with neurones 
expressing markers of primary nociceptive neurones (IB4, CGRP and TRPV 1 ), there was little 
co-localisation at fibre level. From this they suggested that CB1 receptors were expressed 
predominantly on axons of intrinsic spinal cord neurones. Although this could perhaps 
explain the actions of cannabinoids in moderating nociceptive responses at the spinal level 
(Richardson et al., 1998b ), the argument does not appear to take into account the inhibition of 
release of CGRP from peripheral terminals of primary afferents (Richardson et al., 1998a) nor 
do the conclusions correspond with the presence of CB1 receptors in at least some nociceptive 
neuronal terminals (as discussed above). Furthermore, they found a reduction of less than 5% 
of the CB1-like immunoreactivity following a dorsal rhizotomy adequate to eliminate IB4 
staining. It could be suggested that expression on spinal intemeurones and primary afferent 
fibres are both found, given that the reduction in cannabinoid radioligand binding following 
dorsal rhizotomy is only 50% (Hohmann et al., 1999). Explanations for the inconsistency 
with other reports could be that another subtype of receptor is present in the nociceptive 
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neurones, or that there were difficulties with this antibody. Further studies utilising two 
different antibodies raised against the N-terminal of CB1 receptors (Sanudo-Pena et al. , 1999; 
Ahluwalia et al., 2000; Ross et al., 2001) indeed suggest that there may be a difficulty with 
the C-terminal targeted antibody. Sanudo-Pena et al. (1999) found that virtually all cells in 
DRGs (notably including smaller DRG cells) were labelled, and that the presence of CB1-like 
immunoreactivity in the dorsal root and the proximal nerve suggested transport of receptors to 
both peripheral and central terminals of primary afferent neurones (thus underlining the 
functional studies discussed above). Furthermore, immunohistochemical studies on cultured 
, dorsal root ganglion neurones showed that more than half of the neurones which belonged to 
the small soma size subpopulation showed CB1-like immunoreactivity (Ahluwalia et al., 
2000), and that as well as expression on cell bodies, immunolabelling was evident on the 
processes of the cultured neurones (Ross et al., 2001 ). Ahluwalia et al. (2000) also showed 
that almost all TRPVl-like immunopositive neurones (indicative of polymodal, capsaicin 
sensitive, nociceptive neurones) showed CB 1-like immunoreactivity. Interestingly, about 
82% of CB1-like immunopositive neurones showed TRPVl-like immunoreactivity, thus 
providing a correlation with previous studies showing that CB1 receptors are located on 
sensory neurones other than those involved in nociception (Hohmann and Herkenham, 1998; 
Hohmann and Herkenham, 1999b ). Suggestions that altered expression levels in vitro were a 
confounding factor in this study were rebutted by the observation that the extent of the 
expression of TRPVl-like immunoreactivity was similar to that found in intact DRGs. The 
most recent instalment in the examination of CB1 receptor localisation shows that in rat DRG 
no more than 20% of CB1-expressing cells co-stained for TRPVl and that only about 7% of 
TRPVl expressing cells were found to express CB1 mRNA (Bridges et al. , 2003). 
Furthermore, Bridges et al. (2003) found that the majority of the 25% of DRG neurones that 
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expressed CB1 receptors were myelinated A-fibre neurones, which links back to the findings 
by Hohmann and Herkenham (1999b ). 
An interesting finding from Ross et al. (2001) was that immunoreactivity to an antibody 
raised against the CB2 receptor was found in cells within DRG cultures. Although this could 
be as a result of expression on non-neuronal cells in the culture, F-11 cells (a DRG x 
neuroblastoma hybridoma) used in the same study were also found to express CB2 receptors. 
Thus studies utilising antibodies against CB2 receptors on acutely isolated tissue may be 
worthwhile, though a functional effect has not been found yet given that SR144528 (a CB2 
antagonist) did not attenuate the actions of 100 nM WIN 55,212-2 (Ross et al., 2001). 
Therefore, although there has been some debate as to the extent and nature of the location of 
CB1 receptors in primary afferent neurones, on the whole most studies show that at least some 
neurones likely to be nociceptors express CB1 receptors (Hohmann and Herkenham, 1998; 
Sanudo-Pena et al., 1999; Hohmann et al., 1999; Hohmann and Herkenham, 1999a; Hohmann 
and Herkenham, 1999b; Ahluwalia et al., 2000; Ross et al., 2001; Bridges et al., 2003). 
Although localisation studies help to provide an anatomical basis for the peripheral actions of 
cartnabinoids, only functional studies will enable the extent of the actions of cannabinoids on 
nociceptive neurones to be fully understood. Therefore, it is appropriate to examine how 
cannabinoids modulate nociceptive neurones on a cellular basis. Thus in vitro studies using 
cultured DRG neurones are a suitable model as a subset of these neurones are known to 
express the characteristics of nociceptors in viva (Baccaglini and Hogan, 1983; Gold et al., 
1996b). 
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Jn vitro culture studies 
Because of the difficulty in dissecting out primary afferent fibres themselves, in vitro 
studies utilise cultures of the isolated dorsal root ganglion neurone cell bodies that give rise to 
these primary afferent fibres. Cultured nerve cell bodies are found to express receptors 
known to exist at both peripheral and central terminals of the primary sensory neurone. 
Therefore actions of cannabinoid receptor ligands on cultured DRG neurones may reflect 
events that occur centrally and/or peripherally. Utilising such a model, Ross et al. (2001) 
found that both anandamide and WIN 55,212-2 inhibited N-type voltage-gated calcium 
channels via CB1 receptors (as seen by sensitivity to the CB1 antagonist SR141716A). 
Furthermore, this inhibition was pertussis toxin-sensitive suggesting the involvement of Guo 
proteins which have been reported before to mediate cannabinoid receptor effects (Howlett et 
al., 1986). Such an inhibitory action could underlie previous studies that suggest that 
inhibition of neuropeptide release from the terminals of primary nociceptive neurones is 
important in the antihyperalgesic role of cannabinoids (Richardson et al., 1998a; Richardson 
et al., 1998b). Surprisingly, 100 nM WIN 55,212-2 did not noticeably inhibit forskolin· 
stimulated cAMP production (Ross et al., 2001 ), which contrasts with other reports of 
cannabinoids inhibiting the production of cAMP (Howlett and Fleming, 1984; Howlett, 1985; 
Jung et al., 1997). It was suggested though that the inhibition of forskolin~stimulated cAMP 
production in these cells might be too small to be measured experimentally. Interestingly, 
Jung et al. (1997) found that higher concentrations of WIN 55,212-2 were needed to inhibit 
forskolin-stimulated cAMP production than cAMP production stimulated by a receptor 
agonist (isoproterenol) thus suggesting that the effects of WIN 55,212-2 may have been 
counteracted by forskolin in the study by Ross et al. (2001 ). Even a small inhibition of cAMP 
may be functionally significant given the amplification of the cAMP cascade. Also noted in 
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the study by Ross et al. (2001) was that WIN 55,212-2 had an effect in all of the neurones 
tested. 
In another study, Millns et al. (2001) showed recently that HU210 inhibited capsaicin-
evoked calcium responses in cultured DRG neurones via CB1 receptors. Not only does this 
support the existence of functional cannabinoid receptors in DRG neurones, but it also 
reinforces their presence in polymodal nociceptive neurones. This result was supported in the 
more recent study by Ahluwalia et al. (2003) where anandamide was shown to inhibit 
capsaicin-evoked CGRP release. Tognetto et al. (2001) also found that the activation of 
cannabinoid receptors on cultured dorsal root ganglion neurones could inhibit an increase in 
,intracellular calcium concentration, and neuropeptide release, evoked by electric field 
stimulation. This could be due to the inhibition of voltage-gated calcium channels. A more 
recent report by Khasabova et al. (2002), however, found that while the activation of CB 1 
receptors inhibited the response of intermediate diameter neurones to K\ these neurones 
rarely responded to capsaicin. Furthermore, in those neurones most likely to respond to 
capsaicin, small-diameter neurones, there was generally no effect despite the presence of CB1 
receptor immunoreactivity. 
Therefore, the evidence suggests tha~ on balance; functional cannabinoid receptors do exist 
in nociceptive neurones and this localisation is important in their modulatory actions, of 
which the inhibition of neuropeptide release via inhibiting N-type calcium channels is an 
important aspect. Although Ross et al. (2001) concluded that the cannabinoid receptor· 
mediated inhibition of the calcium channels was probably as a result of a direct action of the 
G protein upon the channels themselves, cannabinoids could also mediate their 
antihyperalgesic actions by other intracellular means. One potential route is via their 
inhibitory actions on adenylate cyclase (Howlett and Fleming, 1984; Howlett, 1985; Howlett 
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et al., 1986), the activation of which is known to mediate the peripheral sensitisation of 
nociceptors by inflammatory mediators, leading to primary hyperalgesia. 
Aim 
Given that opioids are known to bind to and activate receptors coupled to the inhibition of 
adenylate cyclase (Minami and Satoh, 1995), and that they too have a peripheral dimension to 
their control of nociception (Stein, 1995), similar mechanisms of action for cannabinoids in 
the periphery were considered. As the activation of µ opioid receptors has been seen to 
prevent the increase in peak TTX-R sodium current induced by PGE2 (Gold and Levine, 
1996), it was decided to investigate whether cannabinoids modulate the PGE2 sensitisation of 
nociceptive neurones. This effect was examined by utilising capsaicin to evoke a change in 
intracellular calcium levels in the subset of cultured DRG neurones that express the TRPVl 
receptor, which include nociceptive neurones. In addition to this, the effect of activating 
another more recently discovered family of G-protein coupled receptors (GPCRs), the 
Sensory Neurone Specific Receptors (SNSRs), was investigated. 
1.4 Sensory Neurone Specific Receptors (SNSRs) 
Cloning of the receptors 
The novel family of GPCRs called Sensory Neurone Specific Receptors (SNSRs), also 
known as Mas-related gene (MRG) receptors, were identified independently by two groups 
- 31 -
(Dong et al., 2001; Lembo et al., 2002). Both studies utilised cloning as a means of 
identifying novel GPCRs that were specific for nociceptive neurones. Cloning involves 
digesting deoxyribonucleic acid (DNA) from a selected source using restriction enzymes and 
then inserting it into a vector which, in turn, is inserted into a host. A range of vectors can be 
employed with plasmids being the principle ones. If it is necessary to clone large pieces of 
genomic DNA then the Bacterial Artificial Chromosome, which is a system based upon the 
single-copy plasmid F factor from Escherichia coli, can be employed (Shizuya et al., 1992). 
In order to make it easier to isolate expressed genes (given that genomic DNA includes non-
'transcribed sections), messenger ribonucleic acid (mRNA) can be reverse transcribed into 
complementary DNA (cDNA) and this can be inserted into a vector. Once vectors containing 
the DNA from a source of interest are inserted into hosts such as E. coli a library is formed 
which can then be utilised to study the selected DNA (for more information, see Howe, 1995). 
Dong et al. (2001) utilised a mutant phenotype of mouse where trkA positive neurones 
(which include a subpopulation of nociceptive neurones) failed to be generated. By 
identifying the cDNA present in a library generated from wild-type neurones, that was absent 
in this mutant population, this enabled genes specifically expressed in these neurones to be 
identified. One of the previously unknown genes was for a GPCR with homology for the Mas 
gene family, which was named mrgAJ (Mas-related gene Al). Additional members of this 
family were found-to be expressed by murine DRG by screening cDNA and BAC libraries 
(mrgsA2-8), and by searching gene databases using mrgAl as the query sequence (additional 
members of the mrgA subfamily, and two closely related subfamilies, mrgB and mrgC). 
Lembo et al. (2002) identified a novel GPCR in rat (rSNSR) after using a cDNA library 
isolated from a primary culture of rat DRG. Subsequently, they identified six novel GPCRs 
(called hSNSRs) from the human genomic library using the sequence for rSNSR as a probe. 
These. GPCRs were noted to have a close relationship with the MRGs. 
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Given the identification of what could be the same receptor family by two different groups, 
there is some confusion regarding the receptor nomenclature. Until this is officially resolved, 
there will be difficulty in knowing which is the more con-ect nomenclature to use, however, 
for the purposes of this thesis SNSR has been adopted. For the hSNSRs identified by Lembo 
et al. (2002), the following correlations were noted: SNSRl is equivalent to hMRGX3 (with 
SNSR2 as its closest relative); SNSR4 is equivalent to hMRGXl (with SNSR3 as its closest 
relative); SNSR6 is equivalent to hMRGX4 (with SNSR5 as its closest relative). 
Also, the number of members of this GPCR family appears to be species dependent with 
Zylka et al. (2003) noting that in rat sensory ganglia there were a core subset of 
approximately four different genes (MrgA, MrgB, MrgC and MrgD). 
Localisation 
The name SNSRs derives from their very specific localisation to sensory neurones (Lembo 
et al., 2002). Lembo et al. (2002) reported that the expression of SNSR mRNA was confined 
to a subset of small-diameter neurones in rat DRG and trigeminal ganglia- notably 56% of 
neurones expressing SNSR mRNA displayed TRPVl-like immunoreactivity. This suggests 
that SNSRs are expressed by a subset of nociceptive neurones. This was further suggested 
when MrgCJ 1, another name for the rat ortholog, was found in small diameter, IB4-positive 
nociceptive neurones (Han et al., 2002). Interestingly, Dong et al. (2001) found that mrgAs 
and mrgD, the genes encoding the GPCRs, were expressed differently in subsets of murine 
sensory neurones, and were generally expressed in neurones with the trkA receptor for NGF 
but not TRPVl. A recent study by Zylka et al. (2003) examined the Mrg genes found in rats, 
and found that unlike mice, they had just a single MrgA and MrgC gene. In fact in rat DRG it 
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was found that there were principally four different genes (MrgA, MrgB, MrgC and MrgD) , 
defining four different neuronal subpopulations (rMrgA & rMrgD, rMrgB4 & rMrgB5, 
rMrgC, and rMrgC & rMrgB4) all of which bound IB4 and expressed the c-Ret receptor for 
GDNF. All Mrg+ neurones were found to express P2X3 receptors in the rat and all rMrgD+ 
cells were found to express TRPVl. rMrgC, also defined as rSNSRl, was found to be present 
at both peripheral and central terminals ofDRG by Grazzini et al. (2004). When these reports 
are taken together, SNSRs (or MRG receptors) appear to be expressed in a subset of small 
diameter, nociceptive neurones, the exact characteristics of which show subtle differences in 
alternate species. This localisation potentially implicates them in modulating nociceptive 
processmg. 
Agonists and receptors 
Given the identification of these novel GPCRs, agonists which would activate these 
receptors were sought. After screening HEK293 cells stably expressing hSNSR3 or hSNSR4 
using a calcium-mobilization assay, Lembo et al. (2002) found that bovine adrenal medulla 
peptide 22 (BAM 22) was the most potent agonist. However, because the classical opioid 
YGGFM (Met-enkephalin) motif is present in BAM 22, BAM (8-22) was found to be the best 
selective ligand. Han et al. (2002) found that BAM 22 was able to activate mouse MrgAl 
weakly and MrgCl 1 potently. A more recent report from Grazzini et al. (2004) examined rat 
SNSRl and found that the most potent agonist for this receptor was y2-MSH. BAM (8-22) 
was also a full agonist at this receptor but its potency was poor . compared with that at 
hSNSRs. Han et al. (2002) found that y2-MSH was also a potent ligand for mouse MrgCl 1, 
thus helping to confirm its status as the ortholog of rat SNSRl . 
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In general it was found that Mrg receptors could be activated by RF-amide related peptides 
(Han et al., 2002; Dong et al., 2001), of which BAM 22 is a member, and pain-modulating 
opioid peptides such as BAM 22 (derived from proenkephalin) and y2-MSH (derived from 
proopiomelanocortin) (Choi and Lahn, 2003). Han et al. (2002) suggested that post-
processing of the RF amide peptides may determine Mrg receptor-ligand specificity. Such a 
concept fits well with the report by Choi and Lahn (2003) that the extracellular domains of the 
Mrg receptor family display evidence of strong positive selection thus permitting the mosaic 
of Mrg expression by nociceptive neurones to engender a wide range of sensitivity. 
The endogenous agonist of these receptors is unknown, though Zhang et al. (1999) found 
that BAM (8-22) occurred endogenously as a peptidase cleavage product of proenkephalinA-
derived peptide E. The precursor of y2-MSH, POMC, has been detected in rat spinal cord, 
DRG and skin. Thus there is evidence that both BAM (8-22) and y2-MSH could be potential 
endogenous ligands for SNSRs. As for the functional significance of these receptors only rat 
SNSRl has been shown to be of actual functional significance (see below). 
As for the coupling of these receptors in situ, Han et al. (2002) demonstrated that both 
MrgAl and MrgCll receptors are coupled to the Guq/II signaling pathway in mouse 
embryonic fibroblasts by utilising Gu protein knockout mice. This does not, however, deal 
with whether this is the case in neurones, and so this remains to be determined. 
In vivo studies 
The role of these receptors with respect to nociception was partially elucidated by Cao et al. 
(2003) when in a study examining the rat spinal nociceptive flexor reflex they showed that the 
activation of SNSRs by the application of BAM (8-22) resulted in enhanced touch, pinch and 
heat responses. Grazzini et al. (2004) also found that the activation of rat SNSRl produced 
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spontaneous pain behaviour, heat hyperalgesia and mechanical allodynia when injected 
intradermally, and heat hyperalgesia when given intrathecally. 
Aim 
The reports noted above do not examine either the real role of SNSRs at the cellular level in 
sensory neurones or the signalling pathways involved with SNSRs in real neurones. Given 
the pronociceptive effect of SNSR activation seen in vivo, and the localisation on neurones 
expressing TRPVI, it was decided to examine if the activation of SNSRs resulted in a 
modulation of the excitability of nociceptive neurones, and also if this affected TRPV 1 itself. 
The possibility of examining the signalling pathway involved in real neurones, if an effect 
was seen, could then be possible. 
Hypotheses to be tested 
1) The activation of cannabinoid receptors on nociceptive neurones attenuates the 
sensitisation of these neurones by PGE2• 
2) The activation of SNSRs:-
a. enhances the excitability of nociceptive neurones, 
b. activates an intracellular signalling pathway involving kinases, and 
c. modulates TRPVI . 
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Chapter 2 
Materials and Methods 
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2.1 Primary culture of dorsal root ganglion neurones 
Dissection 
Neonatal Wistar rats aged 3 to 7 days old were sacrificed by cervical dislocation followed 
by decapitation. A dorsal midline incision through the skin was then made to reveal the 
spinal column. Next, another midline incision was made through the dorsal wall of the spinal 
column to reveal the spinal cord. The spinal cord was removed, and overhanging vertebrae 
were trimmed back slightly to provide a clear view of the ventral part of the spinal column. 
The dorsal root ganglia (DRGs), which are found between the vertebrae on both sides of the 
spinal column towards the ventral surface, were then harvested using ultra-fine forceps into 
2 ml Dulbecco's Phosphate Buffered Saline (DPBS-1; Invitrogen; Cat No. 14040) in a 35 mm 
petri dish. Generally, 40 to 50 DRGs were harvested from one animal. The DRGs were then 
cleaned individually of nerve trunks and obvious connective tissue. 
Dissociation 
DRGs were transferred into 2 ml Medium-I (see Table 2.1 for media formulations) 
containing 0.25% collagenase (type IV; Worthington). DRGs were incubated in this solution 
for 1 hour at 37°C, 5% C02, and were then washed twice with 10 ml Medium-2 before being 
triturated in 2 ml Medium-2; first using a 0.6 mm diameter needle, and then a 0.5 mm 
diameter needle until the DRGs had been visibly broken up. The dorsal root ganglion (DRG) 
cell suspension was washed through a 40 µm nylon cell strainer (BD Biosciences) with 8 ml 
Medium-2, before being centrifuged for 10 minutes at 1 OOO rpm. This filtration step is 
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expected to increase the percentage of cultured dorsal root ganglion (DRG) neurones 
expressing TRPV 1, as these are at the smaller end of the size range (Michael and Priestley, 
1999). 
Plating on glass coverslips for calcium imaging and immunocytochemistry 
The DRG cell pellet was resuspended in 1 ml Medium-3, and an approximate count ofDRG 
neurones present in the suspension was then carried out using a haemocytometer. The 
concentration of neurones in the suspension was altered to approximately 5x104 neurones 
ml-1. 0.5 ml of this suspension were plated onto glass coverslips (13 mm diameter, thickness 
1; BDH) previously coated for at least 30 minutes with 4.167 µg poly-L-lysine hydrobromide 
(cell culture grade; Sigma) and overnight with 2.5 µg laminin (BD Biosciences). Coverslips 
were kept at 37°C, 5% C02, and after 48 hours the Medium-3 was removed and replaced with 
0.5 ml Medium-4. 
Plating on 35 mm petri dishes for electrophysiology 
The DRG cell pellet was resuspended in 0.5 ml Medium-3, and an approximate count of 
DRG neurones present in the suspension was then carried out using a haemocytometer. The 
concentration of neurones in the suspension was altered to approximately 1.33x105 neurones 
mr
1
• 30 µl of this suspension was added to the centre of 35 mm petri dishes previously coated 
for at least 30 minutes with 8.334 µg poly-L-lysine hydrobromide. The petri dishes were kept 
at 37°C, 5% C02 for 30 minutes before 2 ml Medium-3 was added to each dish and they were 
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then returned to 37°C, 5% C02. After 48 hours, the Medium-3 was removed and replaced 
with 2 ml Medium-4. 
Media Formulations 
Media Ingredients 
Medium-I Dulbecco's Modified Eagle Medium (high glucose; Cat No. 41966) with 1 % 
penicillin-streptomycin (Cat No. 15070) and 2 mM L-glutamine; all from 
' 
Invitrogen 
Medium-2 Medium-I with 10% fetal bovine serum (FBS; heat inactivated; Cat No. 
10108; Invitrogen) 
Medium-3 Medium-2 with 50 ng m.r1 nerve growth factor (NGF; murine, 7S; 
Promega) and 1.25 µg m.1-l cytosine 1-P-D-arabinofuranoside (Ara-C; 
Sigma) 
Medium-4 Medium-I with 1% N-2 supplement (Invitrogen), 50 ng m.1-1 NGF and 
0.5 µg m.1-1 Ara-C 
Table 2.1 Details of various media formulations employed 
- 40 -
2.2 Calcium Imaging 
Fluo-4 loading 
Neonatal rat DRG neurones, cultured for 3 days on glass coverslips, were incubated in 
Medium-I containing 8 µg mr1 Fluo-4 AM (Molecular Probes) for 30 to 45 minutes at 37°C, 
5% C02. Fluo-4 AM is a cell permeant ester form of Fluo-4 that is cleaved following uptake 
into the cell by intracellular esterases to form Fluo-4 that is cell impermeant. The intensity of 
excited emission of Fluo-4 increases when it has Ca2+ bound and it can thus be used to 
measure the intracellular calcium concentration. At room temperature, based upon assays 
carried out by Molecular Probes, the dissociation constant of Fluo-4 for calcium (Kd) is 
345 nM, the absorption maximum is 494 nm, and the emission maximum is 516 nm. The free 
intracellular calcium concentration is related to the fluorescence by the following formula 
(Free intracellular calcium concentration = Kd(F-Fmin)/(Fmax-F)). In the current study, 
however, it was not necessary to calculate the intracellular calcium concentration as a 
comparison of the normalised fluorescence was adequate. 
Imaging of neurones 
Coverslips were loaded into a confocal flow chamber (Figure 2.1; after McNaughton et al. 
(1990)), which was then filled with Hank's balanced salt solution (HBSS in mM: 140 NaCl, 4 
KCl, 10 HEPES, 1.8 CaCh, 1 MgCh, 5 glucose; pH 7.4 with NaOH). The level of Ca2+ 
present in the neurones was determined by using a Nikon Eclipse TE300 microscope, with a 
20x, water-immersion Plan Fluor objective, connected to a Bio-Rad micro-Radiance Confocal 
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Figure 2.1 Technical diagram of the confocal flow chamber 
The confocal flow chamber viewed from the top (a), in a lengthways bisection (b) 
and from the bottom ( c ). The main Duralumin component (red) contains a central recess into 
which the coverslip is placed cell-side down. The coverslip is retained in place by a Duralumin lid 
(yellow) which is secured by Duralumin brackets. The solution containing part of the chamber 
(light grey; approximate volume 0.4ml) is bounded on the other side by perspex (blue), with a 
22mm diameter coverslip (BDH; borosilicate glass; thickness number 1) (green) completing the 
enclosure. Two pieces of silicon tubing (green) surround the inflow and outflow (indicated by 
arrows). All of these components are held together with silicon sealant. 
Scanning system (model MRAG2) to detect the emission from Fluo-4, which was excited by 
an air-cooled argon/ion laser filtered to produce a beam of 488 nm. Thirty percent of the 
excitation light was reflected down to the sample using an 80:30 beam splitter that relies on 
the polarisation of light to distinguish laser light from light returning from the sample. 
Subsequently, eighty percent of emitted light passed through the 80:30 beam splitter to be 
completely channelled to a single photomultiplier before which it was filtered through a 
500 nm long-pass filter to remove any excitation light. Laser Sharp software (BioRad; 
version 3.2, with Time Course attachment) was used to record fluorescence and transmission 
images (with a Kalman filter, n=2) every 3 seconds, and these were saved for later analysis. 
tJl experiments were carried out at 21±1 °C. 
The confocal flow chamber was designed to allow the perfusion of the cultured DRG 
neurones on the coverslip while calcium imaging was carried out using the confocal scanning 
system discussed above. The solution-containing part of the chamber was designed to allow 
laminar flow in one direction. An enclosed chamber design with open ends was used, as this 
prevented the chamber running dry while limiting the presence of bubbles in the chamber. A 
chamber volume of approximately 0.4 ml was selected as this permitted a rapid change of 
solution in the chamber (i.e. with a flow rate of 3.5 ml min-1 the solution in the chamber was 
completely changed in just under 7 seconds). 
Time course 
The confocal flow chamber was perfused with HBSS or drug treatments at approximately 
3.5 ml min-1 by means of a gravity perfusion system. When test solutions were being added, 
the perfusion of HBSS or drug treatment was stopped; this was resumed after the addition was 
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completed. Test solutions were added manually using a 2 ml syringe, and this flow replaced 
the HBSS flow. 
Neurones were exposed to HBSS and 0.01 or 0.02% DMSO (dimethyl sulfoxide; Sigma) for 
15 seconds each in order to test for the effects of solution addition, and the effects of the 
vehicle, respectively. This was followed by a 15 second exposure to a 25 mM KCl solution 
(in mM: 119 NaCl, 25 KCl, 10 HEPES, 1.8 CaCh, 1 MgCh, 5 glucose; pH 7.4 with NaOH) in 
order to confirm the identity of neurones. 100 nM capsaicin (Calbiochem; 5 mM stock 
solution in DMSO) was then applied for 15 seconds, every four minutes, to activate the 
transient receptor potential vanilloid 1 (TRPV 1) cation channels. Drug treatment solutions 
were applied for a specified length of time before the sixth capsaicin addition (which also 
contained the drug treatment). Four minutes after the eleventh capsaicin addition, 100 µM 
o.,~-methyleneadenosine 5'-triphosphate lithium salt (o.,~-MeATP; Sigma) was applied for 15 
seconds to identify those neurones expressing P2X3 receptors. On the completion of the 
protocol, the perfusion of HBSS was stopped and 10 µM ionomycin ( calcium salt; Sigma; in 
(in mM) 30 CaCh, 125 KCl, 10 HEPES; pH 7.4 with NaOH) was added in order to provide the 
maximum fluorescence (Fmax). 
Analysis 
The pre-recorded fluorescence images were analysed using either Laser Sharp software, 
with Time Course attachment, or LaserPix (version 4.0, BioRad). Regions believed to 
contain individual DRG neurones were selected and the level of fluorescence (F) in each of 
these regions was recorded throughout the time course. The dark image value for a region 
(which is the signal collected when the laser shutter is closed and thus represents the dark 
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noise of the photomultiplier of the confocal system) was subtracted from all of the readings 
for that region. The readings were then standardised by dividing by the maximum value 
recorded for that region (Fmax) to generate values in F!Fmax· Figure 2.2 shows a plot of F!Fmax 
against time for one such region of interest. 
Because of the great number of regions of interest handled and the variability in the 
responses of different neurones, it was decided to develop an automated system capable of 
objectively handling the data to prevent any bias in the analysis. A spreadsheet (Microsoft 
Office Excel 2000; Microsoft Corporation) was designed to assess the characteristics of each 
region of interest by checking if the data for the region met a range of criteria which indicated 
that it covered a healthy neurone that repeatedly responded to capsaicin, showed negligible 
vehicle artefact (i.e. a response to the addition of the solvent itself), and had loaded well with 
the Fluo-4 AM. By ensuring that a region of interest fell within this range of criteria, it was 
possible to minimise the noise associated with the variability of the responses. The criteria 
(where peaks are always as compared to the averaged baseline for the 30 seconds preceding 
the addition of the test solution) were as follows:-
a) Dye loss: that the highest reading of fluorescence was generated after the addition of 
ionomycin. This controls for rapid dye loss by leaking. 
b) Cell is a neurone: that within 30 seconds of the start of addition of 25 mM KCl a peak 
where the increase in F!Fmax was equal to or greater than 0.05 occurred. This 
identified that the cell in the region of interest was in fact a neurone as the KCl 
solution results in the depolarisation of cell membranes, and neurones are the only 
cells present which express voltage-gated calcium channels. 
c) Consistency of responses: that within 75 seconds of the start of the fourth and fifth 
capsaicin additions a peak where the increase in F/Fmax was equal to or greater than 
0.075 occurred. This ensured that the selected neurone was responding adequately, 
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, Figure 2.2 Repeated capsaicin additions to a cultured DRG neurone 
treatment 
a,[3-Me-ATP 
capsaicin 
KC! 
For the duration of the time points indicated by bars the following solutions are normally 
added: 25 mM KCl, 100 nM capsaicin and 100 µM a,P-Me-ATP. In addition, the above 
example trace shows a drug treatment (in this case 100 nM WIN 55,212-2 and 1 µM PGEi) 
being applied for two minutes between the fifth and sixth capsaicin additions. The vertical 
lines with arrowheads adjacent to the calcium transients indicate the increases in intracellular 
calcium concentration evoked by the fifth, sixth, seventh and eighth capsaicin additions. 
and with some consistency, to the addition of capsaicin. Neurones excluded were 
those that did not respond repeatedly to capsaicin and those that demonstrated 
dramatic alternation in their response to capsaicin such that alternate peaks were very 
small. Figure 2.3(a) demonstrates one such excluded neurone. 
d) Artefacts: that within 30 seconds of the start of addition of HBSS (applied manually) 
and 0.01 or 0.02% DMSO no peak where the increase in F!Fmax: was equal to or greater 
than 0.05 occurred. Thus no neurone displaying a response to the physical addition of 
a test solution (e.g. HBSS) or a response to the vehicle of the test solution (i.e. DMSO 
solution) was included in the analysis. As such, all responses could be deemed to be 
due to the active component of the test solution being added. 
e) Adequate recovery from response: that the baseline prior to the sixth capsaicin 
addition was within 20% of the value of the baseline prior to the fifth capsaicin 
addition. This ensured that the neuronal response to the fifth capsaicin addition had 
adequately subsided before the sixth capsaicin addition. The trace of a neurone 
excluded by this rule is displayed in Figure 2.3(b ). 
f) Stable baseline: that during the 30 seconds preceding the fifth capsaicin addition all 
the F!Fmax: readings were within 0.08 in value. This check prevented the inclusion of 
neurones with a highly erratic baseline, which could confound the automated reading 
of peak heights. Figure 2.4(a) is a trace of a neurone excluded because of its highly 
erratic baseline. 
g) Neuronal health: that the averaged baseline during the 30 seconds prior to the fifth 
capsaicin addition was no more than 0.125 greater in F!Fmax: value than the averaged 
baseline during the 30 seconds prior to the addition of 25 mM KCl. This was to 
exclude those neurones of poor health that demonstrated inadequate recovery from 
initial treatment with either KCl or capsaicin (Figure 2.4(b)). 
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Figure 2.3 Traces exemplifying exclusions made by the automated analysis system. 
(a) is a trace which was excluded from analysis because it did not have an adequate response 
to the fourth addition of capsaicin. (b) is an excluded trace because there was not an adequate 
recovery in fluorescence after the fifth addition of capsaicin. 
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Figure 2.4 Traces exemplifying exclusions made by the automated analysis system. 
(a) is an excluded trace because of its highly fluctuating baseline. (b) is a trace with a high 
intracellular calcium concentration that is sustained from the response to the first capsaicin 
addition. This is indicative of an unhealthy neurone, and as such this trace is excluded from 
the analysis. 
I 
II 
In general, the above limits were set to minimise the risk of including any region of interest 
demonstrating fluctuations liable to be interpreted as peaks by the automated analysis, while 
preventing the exclusion of valid regions of interest. They were determined by visually 
comparing a selection of traces with the manner in which the automated analysis dealt with 
the corresponding regions of interest. 
If all these criteria were satisfied, then the peak values within 75 seconds of the start of the 
fifth and sixth capsaicin additions were obtained, and then the ratio of the value for the sixth 
capsaicin addition to the value for the fifth capsaicin addition (Ratio 6/5) was calculated. 
Similarly, Ratio 7 /5, Ratio 8/5, and the ratio of the areas for the peaks evoked by the fifth and 
sixth capsaicin additions (AreaRatio 6/5) were calculated. 
Neurones were determined to be sensitised or not (according to the criteria discussed in 
Chapter 3), and the percentage of neurones sensitised, as compared with the total number of 
neurones for which ratios had been calculated, was determined for each coverslip. The mean 
of the percentages of neurones sensitised for the set of coverslips associated with a particular 
drug treatment was then calculated, as was the associated standard error of the mean (s.e.m.). 
The s.e.m. was in fact the estimated standard error of the sample mean, and was calculated by 
using Microsoft Office Excel 2000 to divide the sample standard deviation of these 
percentages by the square root of the sample size (i.e. the number of coverslips ). The 
mathematical formula used to calculate the sample standard deviation was as follows:-
(n-1) 
The means associated with different drug treatments were then compared with the control data 
and each other using a one-way analysis of variance (ANOVA) with a Bonferroni post hoe 
test (SPSS for Windows; version 9.0.1; SPSS Inc.). If the difference between two means had 
a probability ofless than 0.05, it was deemed statistically significant. 
Ii 
In addition to assessing how a drug treatment affected those DRG neurones that repeatedly 
responded to capsaicin, the phenotype of the general population of neurones present (based 
upon their responses to capsaicin and a,P-Me-ATP) was examined. In order to characterise as 
wide a range of DRG neurones as possible, the inclusion criteria listed above were relaxed. 
Only points (a), (b), (d), and (f) (which ensure no significant dye loss, that the cell is a 
neurone, that artefacts are absent, and that the baseline is stable) were required to be met in 
order that responses to capsaicin and a,P-Me-ATP could be assessed. The other inclusion 
criteria, ( c ), ( e ), and (g), were not necessary as consistent, repetitive responses to capsaicin are 
not required to establish if a neurone responds to capsaicin. This also made it possible to 
lower the criteria for determining if a neurone responded to capsaicin as there was no need to 
' 
guard against dramatic alternation in the response to capsaicin. As such, if within 75 seconds 
of the start of the first, second or fifth capsaicin additions, a peak where the increase in F IF max 
was equal to or greater than 0.06 occurred, then the neurone was deemed to respond to 
capsaicin. If within 30 seconds of the start of the addition of a,P-Me-ATP, a peak where the 
increase in F!Fmax was equal to or greater than 0.06 occurred, then the neurone was deemed to 
respond to this agonist. Using this same criterion (with respect to inclusion, and the limits for 
peaks evoked by capsaicin), neurones that were non-responsive to the first, second, third, 
fourth and fifth capsaicin additions but did respond to the sixth capsaicin addition (after 
exposure to the drug treatment) were identified, as they were believed to be correlates of the 
'silent' nociceptors ~eported elsewhere (Schmidt et al., 1995). 
The phenotype of the neurones repeatedly responding to capsaicin, when the neurones were 
exposed to different treatments, was compared using the Chi-square test, assuming that there 
was no difference in the proportion of the different phenotypes. For further information on 
the Chi-square test see Brown and Rothery (1994). 
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2.3 Immunocytochemistry 
Visualisation of epitopes 
Coverslips of neurones were washed three times with DPBS-1 before being exposed to lµM 
phorbol 12-myristate 13-acetate (PMA; Alexis), 5µM BAM (8-22) (courtesy of AstraZeneca) 
or DPBS-1 for a specified time. The neurones were then quickly fixed for 15 minutes at room 
temperature using 4% paraformaldehyde (w/v) with 4% sucrose (w/v) dissolved in 
Dulbecco's Phosphate Buffered Saline (without calcium and magnesium; DPBS-2; 
Invitrogen; Cat No. 14190). For the rest of the protocol all solutions contained 1 % (v/v) fish 
skin gelatin to prevent non-specific binding, and prior to each step the coverslips were washed 
three times for five minutes with DPBS-2. 
Firstly, the membranes of the neurones were permeabilised by exposing them to DPBS-2 
containing 0.2% (v/v) Triton X-100 (Sigma) for 30 minutes at room temperature. Next, the 
neurones were exposed for 1 hour at room temperature to a specified dilution of primary 
antibody (see Table 2.1) in DPBS-2 containing 0.05% (v/v) Triton X-100 and 0.5% (v/v) 
sodium azide (antibody solution) before being left with the primary antibody solution 
overnight at 4 °C. The neurones were then exposed for 1 hour at room temperature to a 
donkey anti-rabbit lgG antibody conjugated to the Alexa Fluor 488 dye (Molecular Probes) 
diluted 1 in 200 in antibody solution. Coverslips were then mounted onto slides using Immu-
Mount (Thermo Shandon). 
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Antibody target Antibody type Source of antibody Dilution used 
PKC-o Rabbit (polyclonal) Non-commercial (Olivier 1 in 1000 
and Parker, 1991) 
PKC-E Rabbit (polyclonal) Non-commercial (V. Vellani 1 in 1000 
after Schaap et al. (1989)) 
PKC-s Rabbit (polyclonal) Upstate biotechnology 1 in 500 
Table 2.1 Primary antibodies and dilutions used in immunocytochemistry studies 
Analysis 
Coverslips were examined using a Nikon Eclipse TE300 microscope, with a 60x, oil-
immersion Plan Apo objective, connected to a Bio-Rad micro-Radiance Confocal Scanning 
system (model MRAG2) to detect the emission from the Alexa Fluor 488 dye, which was 
excited by an air cooled argon/ion laser filtered to produce a beam of 488 nm. The emission 
from the Alexa Fluor 488 dye was isolated using a 560 nm dichroic mirror, and a HQ 515/30 
filter. The photomultiplier gain and iris settings, and the zoom setting were optimised for 
each region of the coverslip examined so as to provide the best conditions for the visualisation 
of PKC translocation. Fifteen random images were collected from each coverslip using the 
Slow scan speed and a Kalman filter (n=3). These images were later analysed using Confocal 
Assistant (version 4.0; Todd Clark Brelje) and the neurones present in them were scored 
positive (for example as Figure 4.13(c)) or negative (for example as Figure 4.13(a)) for clear, 
visible translocation of the PKC isoform being examined. The percentage of neurones 
showing translocation was then calculated for each coverslip. For each isoform, the mean 
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percentage ( and s.e.m.) of those neurones showing translocation was calculated for each of 
the treatments. These percentages were then compared using a one-way ANOVA with a 
Bonferroni post hoe test (SPSS for Windows; version 9.0.1; SPSS Inc.) to assess whether any 
of the treatments caused a significant increase in translocation. 
2.4 Electrophysiology 
Whole cell patch clamping 
Petri dishes of neurones that had been cultured for 1 to 3 days were washed twice with 
DPBS-1 before being filled with HBSS adjusted to 325(±3) mOsmoles with sucrose. A 
neurone of interest-typically one with a healthy membrane appearance, an ellipsoid cell 
body, and off-centre nucleus-was then identified using a Zeiss IM35 microscope with a lOx 11 
objective. With the neurone centred in the field of view, perfusion tubes connected to the 
rapid solution changer (RSC-100; Bio-Logic) were lowered into the petri dish such that they 
were just clear of the bottom, to allow movement without disturbing the petri dish, and at the 
edge of the field of view. 
Pipettes of resistance 2-6 MQ were pulled from borosilicate glass capillaries (GC120F-10; 
Harvard) using a Flaming Brown micropipette puller (model P-80/PC; Sutter Instrument Co.). 
These were filled with intracellular solution (in mM: 135 KCl; 1.6 MgC}i; 10 HEPES; 2 
EGTA; 2.5 Mg-ATP; 0.2 Li-GTP; adjusted to pH 7.3 with KOH, and 310-311 mOsmoles 
with sucrose) before being inserted into a pipette holder containing a AgCl wire. Once the 
pipette holder was connected to the headstage of the patch clamp amplifier (LIM-PC; List-
Medical), the pipette was lowered into the HBSS in the petri dish thus completing the circuit 
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with the AgCl reference electrode in the dish. The pipette offset on the amplifier was then 
adjusted to correct for the potential difference between the pipette and bath solutions. Next, a 
gigaohm seal was achieved between the pipette and the plasma membrane of the neurone. 
The pipette capacitance was compensated by the amplifier circuitry, and the holding 
membrane potential set to - 80 m V. Suction was then applied to the pipette, and the whole 
cell patch-clamp configuration was achieved. Using the amplifier circuitry, the membrane 
capacitance was compensated, and the series resistance (with values generally in the range of 
7.4 to 44.0 MQ) was generally compensated by between 41 % and 51 %. 
Time course 
Once a successful whole cell patch-clamp recording had been achieved, the time course 
protocol was started. The neurone was superfused with HBSS, and every 30s, for ls, was 
exposed to IOOnM capsaicin. While these exposures were repeated, 5µM BAM (8-22) was 
perfused after 150s for 5 minutes. After 25 exposures to capsaicin, IOµM a,~-Me-ATP was 
applied for 5s in order to test for the presence of P2X3 receptors (Ueno et al., 1999). 
The whole-cell current evoked by capsaicin was sampled at 5kHz and filtered at lkHz 
through a 6-pole Bessel filter. All experiments were carried out at room temperature 
(21±1°C), and the le,:igth of the longest axis of the neurone cell body was measured using an 
eyepiece graticule. 
,:, 
Analysis 
Recordings were analysed using CJ.ampfit (version 8.2; Axon Instruments Inc.). A 5Hz 
Gaussian lowpass filter was applied to the data, and the baseline was corrected to zero, before 
measuring the peak current, and 't for a one-term, standard exponential fitted to the decay of 
the response:-
f(t) = IAie - t/r i + C, 
i= l 
using the Simplex fitting method (with zero-shift) (for further information on this fitting 
method see the Clampfit instruction manual). 
Some neurones gave an initial response to capsaicin but the subsequent response was small 
(less than 25 pA) or absent; such neurones were excluded. Neurones were also scored for the 
presence of P2X3 receptors based upon a response to a,~-Me-ATP. The method of 
determining if a neurone was sensitised by BAM (8-22) is detailed in Chapter 5. 
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Chapter 3 
Results: Cannabinoids 
Introduction 
Cannabinoid receptors are the cellular site at which the active ingredients of cannabis 
mediate their effects (Devane et al., 1988). Two such receptors have been clearly identified 
so far: CB1 (Matsuda et al., 1990) and CB2 (Munro et al., 1993). The analgesic action of 
cannabinoids (Abel, 1979) has been found to be mediated via these receptors. This action was 
originally found to occur via a mechanism within the central nervous system (CNS) (Meng et 
al., 1998). Recent reports, however, have shown the presence of cannabinoid receptors on 
primary afferent neurones (Hohmann and Herkenham, 1999b; Ahluwalia et al., 2000) and that 
~annabinoids can modulate nociception by a peripheral mechanism of action (Calignano et 
al., 1998; Richardson et al., 1998b ). In addition, functional cannabinoid receptors have been 
shown on cultured dorsal root ganglion (DRG) neurones (Ross et al., 2001; Tognetto et al., 
2001; Millns et al., 2001). A pharmaceutical based upon activating peripheral cannabinoid 
receptors, but not central cannabinoid receptors, would be clinically beneficial as it would 
avoid psychoactive side effects which make cannabis less desirable as an analgesic drug. 
It was therefore decided to examine at the cellular level how the activation of cannabinoid 
receptors affected the response of nociceptive neurones. This can be done in a controlled in 
vitro Setting as cultured DRG neurones are known to express the characteristics of nociceptors 
in viva (Baccaglini and Hogan, 1983; Gold et al., 1996a; Cesare and McNaughton, 1996). Of 
those primary afferents responding to noxious stimuli, a subset are identified by the 
expression of the transient receptor potential vanilloid 1 (TRPV 1) cation channel (T ominaga 
et al., 1998), and capsaicin was used to activate these receptors (Caterina et al., 1997). 
Capsaicin sensory neurones are known to show tachyphylaxis on repeated stimulation 
(Docherty et al., 1996; Koplas et al., 1997), and thus in order to be able to easily assess the 
effect that a drug treatment has, it was necessary to repeatedly apply capsaicin. Repeated 
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application ensured that any tachyphylaxis in the response to capsaicin had plateaued before 
the effect of the drug was assessed. Neurones were loaded with a fluorescent marker for 
calcium (Fluo-4) to monitor their intracellular calcium level as a means of measuring the I [ 
increase in intracellular calcium concentration from TRPVl activation. After five additions 
of 1 OOnM capsaicin, the drug treatment was applied. Six further capsaicin additions were 
made, before an application of 1 OOµM a,~-Me-A TP was made in order to test for the 
expression of ATP-gated ion channels containing the P2X3 subunit (Figure 2.2). This allowed 
the phenotype of the nociceptive neurones monitored to be further investigated. 
For neurones responding repeatedly to capsaicin, the ratio of the calcium transients evoked 
py the fifth and sixth capsaicin additions was calculated (Ratio 6/5). In order to assess if a 
treatment resulted in a sensitisation of the response of neurones to capsaicin, control data in 
the absence of drug treatment was collected (Figure 3.l(a); black bars; n=90). These data 
were seen to follow a normal distribution with a mean of slightly less than one (0.917308; 
Figure 3.l(a); green dashed line) indicating that although the tachyphylaxis had subsided by 
the fifth capsaicin addition, it was still ongoing to some extent. The 95% two-tailed 
confidence limits for Ratio 6/5 were then determined for the control data by utilising the range 
around the mean of 1.96 times the sample standard deviation (0.076276 and 1.75834; Figure 
3.l(a); red and blue dashed line, respectively). This enabled data from a drug treatment 
experiment to be compared with it. 1.92±1.92% of neurones from the control data fell above 
the upper confidence limit which is close to the expected 2.5% given the 95% confidence 
limit. 
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Figure 3.1 WIN 55,212-2 does not affect nociceptor response to 100 nM capsaicin. 
(a) A histogram displaying the percentage of neurones from control (black, n=90) and 
treatment (grey, n=62) experiments in each range ofratios comparing the size of the sixth 
capsaicin-evoked calcium transient against the size of the fifth transient (Ratio 6/5). 
The single black line plot denotes the Gaussian distribution fitted to the control data, with the 
vertical dashed lines denoting the lower 95% confidence limit (red), the mean (green), and the 
upper 95% confidence limit (blue) of this distribution. (b) A bar chart displaying the mean 
percentage of neurones with s.e.m. in control (nexp=I3) and treatment (nexp= lO) experiments 
where the value of Ratio 6/5 is greater than the upper 95% confidence limit in figure (a) . 
Cannabinoid receptor activation in a non-sensitised model 
In order to test the effect of cannabinoid receptor activation on the response of these TRPVl 
expressing neurones, it was necessary to choose an appropriate agonist. The cannabinoid 
receptor agonist WIN 55,212-2 was selected because of its known efficacy at both CB1 and 
CB2 receptors (Pertwee, 2000) thus ensuring that both known cannabinoid receptors were 
activated. 100 nM WIN 55,212-2 was applied for two minutes prior to the sixth capsaicin 
addition. The Ratio 6/5 data for neurones treated with WIN 55,212-2 (Figure 3.l(a); grey 
bars; n=62) was compared against the confidence limits determined for the control data. If a 
neurone had a ratio that fell below the lower 95% confidence limit, it was deemed to have 
been desensitised, and if it had a ratio that was above the upper 95% confidence limit, it was 
deemed to have been sensitised. The mean percentages ( and the standard errors of the means) 
of neurones sensitised (Control=l.92±1.92%; 100 nM WIN 55,212-2=1.ll± l.11%; Figure 
3.l(b)) were obtained for each set of coverslips (Control nexp=I3; WIN 55,212-2 nexp=lO), and 
no significant difference between the control and WIN 55,212-2 data was seen. Because of 
the magnitude of the variance of the control data, the range within which neurones could be 
deemed to be desensitised (i.e. from O to the lower confidence limit) was rather small and 
prevented meaningful analysis ( e.g. no control neurones fell within this range and for the 
WIN 55,212-2 experiments only 1±1% were present). If the neurones were less variable in 
their responses, desensitisation might have been easier to quantify. This of course raises the 
problem of being able to assess if cannabinoid receptor activation results in attenuation of the 
response of nociceptive neurones in a non-sensitised state. 
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Prostaglandin E2 (PGE2) as a model of sensitisation 
Jn viva studies showed that the activation of cannabinoid receptors in the periphery is 
antihyperalgesic (Calignano et al., 1998; Richardson et al., 1998b). Therefore, given that the 
sensitisation of nociceptive neurones underlies primary hyperalgesia (Meyer & Campbell 
1981; La Motte et al., 1982), it was decided to examine the effect of WIN 55,212-2 when the 
cultured neurones were in a sensitised state. In order to obtain sensitised neurones it was 
necessary to find a suitable agent. PGE2 is a major component of inflammatory exudates, and 
plays a role in the initiation of primary hyperalgesia. Previous reports have shown that it is 
able to sensitise nociceptive neurones in culture (Baccaglini and Hogan, 1983; Nicol and Cui, 
1994; Cui and Nicol, 1995; Stucky et al., 1996; Gold et al., 1996a) via the activation of the 
cyclic 3 ',5' -adenosine monophosphate/Protein Kinase A ( cAMP/PKA) pathway (Taiwo et al., 
1989; Pitchford and Levine, 1991; Taiwo and Levine, 1991; Cui and Nicol, 1995). This is 
especially relevant given that cannabinoid receptors are known to be coupled to the inhibition 
of adenylate cyclase which generates cAMP (Howlett et al., 1986) and thus could be 
modulating the primary hyperalgesia via a mechanism involving the inhibition of cAMP 
production. 
1 µM PGE2 was applied for two minutes prior to the sixth capsaicin addition and resulted in 
an increase in the calcium transient resultant from the sixth application of capsaicin (Figure 
3.2). The Ratio 6/5 data for neurones treated with PGE2 (Figure 3.3(a); grey bars; n=218) was 
compared against the confidence limits determined for the control data. No desensitisation 
was seen in the PGE2 experiments. In control experiments (nexp=l3), 1.92±1.92% neurones 
fell above the upper confidence limit, compared with a significantly higher (at the 0.05 level) 
15.64±4.14% in the PGE2experiments (nexp=l6; Figure 3.3(b)). 
- 57 -
1.0 
0.8 
~ 0.6 
~ 
~ 
0.4 
0.2 
0.0 
0 10 20 30 
Time (minutes) 
40 50 
PGE2 
a ,j3-Me-ATP 
capsaicin 
KCl 
Figure 3.2 PGE2 sensitises a cultured neonatal rat DRG neurone to capsaicin. 
A plot of the intracellular calcium concentration of the neurone ( as measured by F IF max) 
over time. For the duration of the time points indicated by bars the following solutions were 
added: 25 mM KCl, 100 nM capsaicin, 1 µM PGE2 and 100 µM a,p-Me-ATP. The vertical 
lines with arrowheads adjacent to the calcium transients indicate the increases in intracellular 
calcium concentration evoked by the fifth, sixth, seventh and eighth capsaicin additions. 
(a) 18 
16 
14 
"' Q) 
i::: 12 0 
a 
Q) 
i::: 10 
<+-< 
0 
Q) 
oO 8 t<:l 
~ 
u 6 I-< Q) 
~ 
4 
2 
0 
0 l 
(b) 
"' Q) Q) 
oO § ~ a 
Q) Q) 
u i::: 
.... "Cl 
Q) Q) 
P."' Q ·..;::: 
«:1 ·-Q) "' ~ ~ 
<+-< 0 
2 
25 
20 
15 
10 
5 
0 
,., 
., 
Ratio 6/5 
Control 
* 
4 
1 µM 
PGE2 
Treatment 
5 
Figure 3.3 PGE2 sensitises nociceptor response to 100 nM capsaicin. 
6 
(a) A histogram displaying the percentage of neurones from control (black, n=90) and 
treatment (grey, n=218) experiments in each range of ratios comparing the size of the sixth 
capsaicin-evoked c~lcium transient against the size of the fifth transient (Ratio 6/5). 
The single black line plot denotes the Gaussian distribution fitted to the control data, with the 
vertical dashed lines denoting the lower 95% confidence limit (red), the mean (green), and the 
upper 95% confidence limit (blue) of this distribution. (b) A bar chart displaying the mean 
percentage of neurones with s.e.m. in control (nexp=13) and treatment. (nexp=16) experiments 
where the value of Ratio 6/5 is greater than the upper 95% confidence limit in figure (a). 
* indicates that the mean difference is significant at the 0.05 level. 
In addition to looking simply at the transient height, the ratio of the area under the transients 
evoked by the fifth and sixth capsaicin additions was calculated (AreaRatio 6/5) (Figure 
3.4(a)). An increased area, with a broadened response, after treatment with PGE2 could be 
indicative of a decreased off rate between capsaicin and TRPVl resulting in prolonged 
activation. Such an effect is evident in Figure 3.2. The mean for control data in this case was 
also just less than one (0.989988), but the sample standard deviation was larger resulting in an 
upper 95% confidence limit of 2.62513. Again, when the percentage of neurones sensitised 
was examined (Figure 3.4(b)), there was a significant difference (at the 0.05 level) between 
the control data (4.01±2.84%) and the PGE2 data (25.82±5.97%). Thus the application of 
1 µM PGE2 for two minutes results in a significant proportion of neurones being sensitised in 
their response to capsaicin, and a direct effect on TRPVl is suggested. The fact that a greater 
percentage of neurones (approximately 26%) were seen to be sensitised by PGE2 when 
AreaRatio 6/5 was examined compared with Ratio 6/5 (where only approximately 16% of 
neurones were sensitised) implies that a direct sensitisation of TRPVl plays a more 
significant role than a sensitisation of other components that may be involved in the 
generation of the calcium transient. The involvement of other components in the generation 
of the calcium transient, such as voltage-gated calcium channels, is discussed in Chapter 6 
(Section 3). 
The duration of this sensitisation was assessed by examining the ratios of the calcium 
transients evoked by_the seventh and eighth capsaicin additions to the fifth capsaicin addition 
(Figure 3.5). There was no significant difference between these ratios for control and PGE2 
experiments. The reason for the high mean percentage of the control Ratio 7 / 5 is because of a 
single coverslip giving an outlier result. Removing it from the analysis, however, did not 
result in any change to the significance. Thus the sensitisation is limited to the capsaicin 
addition immediately after the PGE2 addition. 
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Figure 3.4 PGE2 increases the area of the capsaicin-evoked calcium transient. 
(Same as figure 3.3 except that AreaRatio 6/5 is being examined) 
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Figure 3.5 Sensitisation by PGE2 is restricted to the subsequent capsaicin addition. 
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The phenotype of the neurones present in these experiments was assessed in order to see if 
the subset of neurones sensitised by PGE2 differed from either the general population of 
neurones or the subset of neurones which repeatedly responded to capsaicin. Neurones fell 
into four categories: those responsive to neither capsaicin nor a,P-Me-ATP (Figure 3.6(a)), 
those responsive to capsaicin only (Figure 3.6(b)), those responsive to both capsaicin and a,P-
Me-ATP (Figure 3.7(a)), and those responsive to a,P-Me-ATP only (Figure 3.7(b)). Figure 
3.8(a) displays the number of neurones falling into each category for all of the PGE2 
experiments, and Figure 3.8(b) provides a comparison amongst all neurones (black), those 
that met the criteria laid out in Chapter 2 for a stable and noise-free repeated capsaicin 
response (light grey), and those out of this latter category that were sensitised by PGE2 ( dark 
grey). From Figure 3.8(b) it appears that neurones repeatedly responding to capsaicin are just 
as likely to respond to a,P-Me-ATP as to be non-responsive to it. However, those responding 
to a,P-Me-ATP appear to be less likely to be sensitised compared to those that do not respond 
though this is not statistically significant (Chi-square test). 
Figure 3.9 shows a recording from a cultured DRG neurone that is a correlate of the 'silent' 
nociceptors described in the introduction (Schmidt et al., 1995) which become responsive in 
the presence of a sensitising factor. In experiments where PGE2 is applied for two minutes 
9.59% of neurones were deemed to be 'silent' nociceptors. By comparison, only 0.81 % of 
neurones in control experiments met the criteria for 'silent nociceptors' . 
Cannabinoid receptor activation in a sensitised model 
Using the above model of sensitisation, 100 nM WIN 55,212-2 was co-applied with 1 µM 
PGE2 in order to activate cannabinoid receptors while nociceptive neurones were in a 
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Figure 3.6 Example plots of DRG neurones that Ratio 6/5 values were not calculated for. 
(a) shows a neurone that is not responsive to capsaicin or a,p-Me-ATP. (b) shows a neurone 
responsive to capsaicin only. The plots are of the intracellular calcium concentration of the 
neurones (as measured by F/Fmax) over time. For the duration of the time points indicated by 
bars the following solutions were added: 25 mM KCl, 100 nM capsaicin and 100 µM 
a ,p-Me-ATP. 
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Figure 3.7 Example plots of DRG neurones that Ratio 6/5 values were not calculated for. 
(a) shows a neurone that is responsive to both capsaicin and a,P-Me-ATP. (b) shows a 
neurone responsive to a,P-Me-ATP only. The plots are of the intracellular calcium 
concentration of the neurones (as measured by F/Fmax) over time. For the duration of the time 
points indicated by bars the following solutions were added: 25 mM KCl, 100 nM capsaicin 
and 100 µM a,p-Me-ATP. 
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Figure 3.8 Characterisation of DRG neurones from PGE2 sensitisation experiments. 
(a) A pie chart displaying the number of neurones analysed that responded to neither 100 nM 
capsaicin nor 100 µM a,P-Me-ATP (red), to only capsaicin (orange), to both capsaicin 
and a,p-Me-ATP (yellow), and to only a,p-Me-ATP (green). (b) A bar chart displaying 
the same information as in (a) (black), and in addition, displaying the number of neurones in 
each category for the subset of neurones that gave a stable response to capsaicin (light grey), 
and for the neurones ofthis subset that had a Ratio 6/5 value greater than the upper 95% 
confidence limit denoted in figure 3.3(a) (dark grey). 
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Figure 3.8 Characterisation of DRG neurones from PGE2 sensitisation experiments. 
(a) A pie chart displaying the number of neurones analysed that responded to neither 100 nM 
capsaicin nor 100 µM a,p-Me-ATP (red), to only capsaicin (orange), to both capsaicin 
and a,p-Me-ATP (yellow), and to only a,P-Me-ATP (green). (b) A bar chart displaying 
the same information as in (a) (black), and in addition, displaying the number of neurones in 
each category for the subset of neurones that gave a stable response to capsaicin (light grey), 
and for the neurones of this subset that had a Ratio 6/5 value greater than the upper 95% 
confidence limit denoted in figure 3.3(a) (dark grey). 
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Figure 3.9 Example plot of a 'silent' nociceptor. 
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The plot is of the intracellular calcium concentration of the neurone ( as measured by F IF max) 
over time. For the duration of the time points indicated by bars the following solutions were 
added: 25 mM KCl, 100 nM capsaicin, 1 µM PGE2 and 100 µM a,p-Me-ATP. 
sensitised state. The Ratio 6/5 data for neurones treated with PGE2 and WIN 55,212-2 
(Figure 3.lO(a); grey bars; n=l60) was compared against the confidence limits determined for 
the control data. Neither in the control nor the PGE2 and WIN 55,212-2 experiments was any 
desensitisation seen. In control experiments (nexp=l3), 1.92±1.92% neurones fell above the 
95% confidence limit, compared with 10.03±3.47% in the PGE2 and WIN 55,212-2 
experiments (nexp=l6; Figure 3.lO(b)). These two values were not significantly different 
however, and neither was the percentage of neurones sensitised in the presence of WIN 
55,212-2 and PGE2 from the percentage sensitised in the presence of PGE2 only 
(15.64±4.14%). 
Again the ratio of the area under the transients evoked by the fifth and sixth capsaicin 
additions was calculated (AreaRatio 6/5) (Figure 3.1 l(a)). As with the Ratio 6/5 data, there 
was no significant difference between the control data (4.37±2.41%), and the PGE2 and WIN 
55,212-2 data (16.78±5.04%) (Figure 3.1 l(b)). 
As with the PGE2 experiments, the phenotype of the neurones present in these experiments 
was assessed. Figure 3.12(a) displays the number of neurones falling into each category. 
Figure 3.12(b) provides a comparison amongst all neurones (black), those that met the criteria 
laid out in Chapter 2 for a stable and noise-free repeated capsaicin response (light grey), and 
those sensitised by PGE2 (dark grey). Once again, those neurones not responding to a,~-Me-
ATP appear to be preferentially sensitised, and in this case this is statistically significant (Chi-
square test, significant at 0.05 level, x2=5.538). 
In these experiments where PGE2 and WIN 55,212-2 were applied for two minutes, 5.53% 
neurones were deemed to be 'silent' nociceptors. These 'silent' nociceptors are dealt with 
separately from those neurones which are included in the Ratio 6/5 analysis because their lack 
of a noticeable response to previous capsaicin additions makes it mathematically impossible 
for a sensible ratio to be calculated. It also seems inappropriate to simply include them as 
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Figure 3.10 WIN 55,212-2 does not significantly inhibit sensitisation by PGEr 
(a) A histogram displaying the percentage of neurones from control (black, n=90) and 
treatment (grey, n=1_60) experiments in each range ofratios comparing the size of the sixth 
capsaicin-evoked calcium transient against the size of the fifth transient (Ratio 6/5). 
The single black line plot denotes the Gaussian distribution fitted to the control data, with the 
vertical dashed lines denoting the lower 95% confidence limit (red), the mean (green), and the 
upper 95% confidence limit (blue) of this distribution. (b) A bar chart displaying the mean 
percentage of neurones with s.e.m. in control (nexp=13) and treatment (nexp=16) experiments 
where the value of Ratio 6/5 is greater than the upper 95% confidence limit in figure (a). 
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Figure 3.11 WIN 55,212-2 does not significantly inhibit the PGE2 sensitisation of the area 
of the capsaicin-evoked calcium transient. 
(Same as figure 3.10 except that AreaRatio 6/5 is being examined) 
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Figure 3.12 Characterisation of DRG neurones treated with PGE2 and WIN 55,212-2. 
( As figure 3. 8 but with reference to figure 3 .10( a)) 
sensitised neurones given the range of criteria laid out in Chapter 2 for selecting the 
population of neurones which should be assessed for sensitisation. 
A comparison of the mean value for Ratio 6/5 and AreaRatio 6/5 of those neurones that had 
fallen above the upper confidence limit in control experiments, and sensitised in PGE2 only, 
PGE2 & WIN 55,212-2, and WIN 55,212-2 experiments failed to reveal any significant 
differences between these groups. 
Conclusion 
In summary, it can be seen that the activation of cannabinoid receptors on cultured DRG 
neurones by a two minute application of 100 nM WIN 55,212-2 does not significantly 
suppress the responsiveness of nociceptive neurones to capsaicin nor does it significantly 
suppress the responsiveness of nociceptive neurones sensitised by PGE2. 
The lack of an effect of WIN 55,212-2 in the present circumstances, given that in other 
circumstances the activation of cannabinoid receptors has been shown to inhibit voltage"'gated 
calcium channel currents (Ross et al., 2001) and TRPV 1 mediated increases in intracellular 
calcium (Millns et al., 2001 ), may be as a result of the nature of the technique used. Millns et 
al. (2001 ), who also used calcium imaging, employed a methodology whereby the 
cannabinoid was added between the first and second capsaicin additions, where some 
desensitisation could be expected to be seen on its own anyway. Ross et al. (2001) used the 
patch clamp method to provide a reading of the current flowing through voltage-gated calcium 
channels, and this could be expected to offer greater precision than calcium imaging in 
examining any effect of cannabinoid receptor activation. It must also be remembered that 
more than one component is involved in the generation of the calcium transient, and the Ross 
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et al. (2001) study was looking specifically at voltage-gated calcium channels. The technique 
used in the present study is such that desensitisation as a direct result of capsaicin addition is 
expected to be minimised. Furthermore, the nature of the analysis resulted in a rather small 
range in which neurones could be classified as desensitised. Thus, any assessment of the 
effect of cannabinoid receptor activation, while perhaps being more accurate than the Millns 
et al. (2001) study, may have been hindered both by the coarse nature of the analysis and the 
involvement of multiple components. 
The other theory investigated in the present study was whether the activation of cannabinoid 
receptors attenuated the sensitisation mediated by PGE2. Such an effect could be expected 
given that cannabinoid receptors have been shown to couple to the inhibition of adenylate 
cyclase, and PGE2, a well known sensitising agent, brings about its effects, partially, via the 
activation of adenylate cyclase and PK.A. Thus a form of physiological 'antagonism' might 
be expected to occur. On examination, however, WIN 55,212-2 was not seen to abolish 
sensitisation by PGE2 when the percentage of neurones sensitised was compared. This was 
both with respect to Ratio 6/5, which compares the height of the transient itself, as well as to 
AreaRatio 6/5. Given that some difference does occur, a greater n number may have helped 
to reduce the s.e.m. and thus produce some significance. If the extent of sensitisation 
occurring between those neurones treated with PGE2, and PGE2 and WIN 55,212-2 is 
compared by examining the mean of the Ratio 6/5 values of those sensitised, there is visibly a 
slightly greater tail to the PGE2 data, compared with the PGE2 and WIN 55,212-2 data. 
Again, however, there was no significant difference when a one-way ANOV A (with 
Bonferroni correction) was applied to the data. 
Therefore, given the lack of any significant effect, it was decided to conclude this area of 
work and move onto a different area. Suggestions for future investigations in this area would 
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be to try a greater and/or longer treatment with a cannabinoid receptor agonist preceeding the 
application of PGE2 in the hope that this might result in some significance. 
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Chapter 4 
Results: SNSRs 
Introduction 
The motivation for the work in this chapter comes from Lembo et al. (2002) who reported 
that a novel family of G-protein coupled receptors (GPCRs) was present in small diameter 
sensory neurones, and named them sensory neurone-specific receptors (SNSRs ). They noted 
that a substantial proportion of neurones expressing these receptors also expressed the 
vanilloid receptor (TRPVl) (56%) and that most bound the plant isolectin B4 (IB4) (76%) 
which is characteristic of the non-peptidergic group of nociceptive neurones (Bennet et al., 
1998). Utilising a heterologous expression system, these receptors were found to be 
selectively activated by the 8-22 fragment of the bovine adrenal medulla peptide 22, BAM (8-
22). In the report by Lembo et al. (2002) the physiological function of BAM (8-22) was 
noted as still open for investigation. Further study by Cao et al. (2003) and Grazzini et al. 
(2004) found that in vivo SNSR activation resulted in both nociception and hyperalgesia. A 
fuller understanding of the molecular mechanisms of pathways activated by the SNSRs may 
allow the development of compounds that could inhibit the activation of these receptors and 
thus the subsequent algesia. Cao et al. (2003) and Grazzini et al. (2004) found that the 
response to heat was enhanced by the activation of SNSRs. Given that TRPVl is involved in 
mediating the response of neurones to heat (Tominaga et al., 1998), examining how SNSR 
activation may affect the response of cultured dorsal root ganglion (DRG) neurones to TRPVl 
agonists would provide a means of establishing a cellular mechanism of action for BAM (8-
22). The protocol established in the last chapter, in which repeated additions of capsaicin are 
used to probe TRPVl activity, provides a means by which the effect of a treatment on those 
neurones expressing TRPVI, and thus neurones known to be detectors of noxious stimuli 
(Caterina et al., 1997), can be examined. This same model was used to probe the action of the 
SNSR agonist, BAM (8-22). 
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The exact form that this action takes will depend on the signalling pathway involved. In 
heterologous expression systems SNSR agonists were seen to cause a calcium release from 
subcellular stores that was not affected by pertussis toxin pre-treatment (Lembo et al., 2002; 
Han et al., 2002; Grazzini et al., 2004) but was completely inhibited by a phospholipase C 
(PLC) inhibitor (Han et al., 2002) suggesting that rat SNSRl is a Gag coupled-receptor 
(Grazzini et al., 2004). Thus its actions in DRG neurones could be mediated by either (1,2-
diacylglycerol) DAG activation of Protein Kinase C (PKC) or inositol 1,4,5-triphosphate 
(IP3)-dependent release of calcium from intracellular stores. So far, there is no published 
work on the effect of SNSR activation of cultured DRG neurones. 
Effect of BAM (8-22) 
A four minute application of 5 µM BAM (8-22) between the fifth and sixth capsaicin 
additions resulted in a sensitisation of the sixth response in a subset of neurones (Figure 4.1 ). 
In order to assess more quantitatively the degree to which treatment with BAM (8-22) 
resulted in a sensitisation of the response of neurones to capsaicin, control data were collected 
in the absence of drug treatment (Figure 4.2(a); black bars; n=90), and the 95% confidence 
limits for Ratio 6/5 were determined (0.076276 to 1.75834; Figure 4.2(a); red and blue dashed 
line, respectively). · Jt should be noted that this represents the same control data as those 
presented in Chapter 3. The Ratio 6/5 data for neurones treated with BAM (8-22) (Figure 
4.2(a); grey bars; n=373) were compared against the confidence limits determined from the 
control data. As the lower confidence limit is close to zero, an examination of the percentage 
of those neurones falling below the lower 95% confidence limit is oflittle value. However, if 
the Ratio 6/5 values for the control and BAM (8-22) treatment data are visually compared for 
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Figure 4.1 BAM (8-22) sensitises a cultured neonatal rat DRG neurone to capsaicin. 
The plot is of the intracellular calcium concentration of the neurone. For the duration of the 
time points indicated by bars the following solutions were added: 25 mM KCl, 100 nM 
capsaicin, 5 µM BAM (8-22) and 100 µM a,P-Me-ATP. The vertical lines with arrowheads 
adjacent to the calcium transients indicate the increases in intracellular calcium concentration 
evoked by the fifth, sixth, seventh and eighth capsaicin additions. 
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Figure 4.2 BAM (8-22) significantly sensitises DRG neurones to 100 nM capsaicin. 
( a) A histogram displaying the percentage of neurones from control (black, n=90) and 
treatment (grey, n=373) experiments in each range ofratios comparing the size of the sixth 
capsaicin-evoked calcium transient against the size of the fifth capsaicin-evoked calcium 
transient (Ratio 6/5). The single black line plot denotes the Gaussian distribution fitted to the 
control data, with the vertical dashed lines denoting the lower 95% confidence limit (red), the 
mean (green), and the upper 95% confidence limit (blue) of this distribution. (b) A bar chart 
displaying the mean percentage of neurones with s.e.m. in control (nexp=13) and treatment 
(nexp=I9) experiments where the value of Ratio 6/5 is greater than the upper 95% confidence 
limit in figure (a). * indicates that the mean difference is significant at the 0.05 level. 
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values less than one, the results are fairly congruent suggesting no desensitising effect. If a 
neurone had a ratio that was above the upper 95% confidence limit, it was deemed to have 
been sensitised. The mean percentages (and the standard errors of the means) of neurones · I 
sensitised (Control=l.92±1.92%; 5 µM BAM (8-22)=14.70±2.78%; Figure 4.2(b)) were 
obtained for each set of coverslips (Control nexp=l3; 5 µM BAM (8-22) nexp=19), and there 
was a significant difference at the 0.05 level between the control and BAM (8-22) data. In 
addition, the ratio of the area under the transients evoked by the fifth and sixth capsaicin 
additions was calculated (AreaRatio 6/5) (Figure 4.3(a)). There was, however, no significant 
difference at the 0.05 level with this measurement between the control data (4.37±2.41 %) and 
the BAM (8-22) data (17.92±3.31 %) (Figure 4.3(b)). Thus the application of BAM (8-22) for 
four minutes results in a significant proportion of neurones being sensitised in their response 
to capsaicin when the height of the evoked transients are compared. 
The duration of this sensitisation was assessed by examining the ratios of the calcium 
transients evoked by the seventh and eighth capsaicin additions to the fifth capsaicin addition 
(Figure 4.4). The Ratio 7/5 and Ratio 8/5 values for the BAM (8-22) experiments were not 
significantly greater than these ratios for control experiments. Thus the sensitisation is short-
lived and disappears within 4 minutes of application of BAM (8-22). 
As with the PGE2 experiments, the phenotype of the neurones present in these experiments 
was assessed in order to determine whether the subset of neurones sensitised by BAM (8-22) 
differed from either_ the general population of neurones or the subset of neurones which 
repeatedly responded to capsaicin. Figure 4.5(a) displays the number of neurones falling into 
each category for all of the BAM (8-22) experiments, and Figure 4.5(b) provides a 
comparison amongst all neurones (black), those that met the criteria laid out in Chapter 2 for a 
stable and noise-free repeated capsaicin response (light grey), and those sensitised by BAM 
(8-22) (dark grey). From Figure 4.5(b) it can be seen that for these experiments neurones 
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Figure 4.3 BAM (8-22) does not significantly increase the area of the capsaicin-evoked 
calcium transient. 
(Same as figure 4.2 except that AreaRatio 6/5 is being examined) 
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Figure 4.5 Characterisation of DRG neurones treated with BAM (8-22). 
(a) A pie chart displaying the number of neurones analysed that responded to neither 100 nM 
capsaicin nor 100 µM a,P-Me-ATP (red), to only capsaicin (orange), to both capsaicin and 
a,p-Me-ATP (yellow), and to only a,p-Me-ATP (green). (b) A bar chart displaying the 
same information as in (a) (black), and in addition, displaying the number of neurones in each 
category for the subset of neurones that gave a stable response (light grey), and for the 
neurones ofthis subset that had a Ratio 6/5 value greater than the upper 95% confidence limit 
denoted in figure 4.2(a) (dark grey). 
repeatedly responding to capsaicin are significantly more likely (Chi-square test; x.2=30.14; 
ps0.001) to respond to a,~-Me-ATP than to be non-responsive to it. Such a distribution was 
not seen in these neurones when sensitisation by PGE2 was examined, and highlights the 
importance of assessing the neuronal population for each treatment before examining the 
distribution of those neurones · that were sensitised. Furthermore, this distribution is 
maintained amongst those neurones sensitising to BAM (8-22) (Chi-square test; x.2=4.17; 
ps0.05). 
Figure 4.6 displays a cultured DRG neurone that is a correlate of the 'silent' nociceptors and 
became responsive in the presence of BAM (8-22). In experiments where BAM (8-22) is 
applied for four minutes 5.10% of neurones were classified as 'silent' nociceptors (see 
Materials and Methods section for classification criteria) compared with O. 81 % of neurones in 
control experiments. These neurones were not included when generating a histogram ( e.g. 
Figure 4.2) as mathematically they would give a Ratio 6/5 value of infinity. 
Protein kinase involvement in sensitisation 
Previous studies with other sensitising compounds have revealed the involvement of protein 
kinases in mediating these effects at the cellular level. PGE2, the sensitising inflammatory 
mediator discussed il.1 the previous chapter, has been shown to activate both the cyclic 3 ',5 ' -
adenosine monophosphate/Protein Kinase A (cAMP/PKA) pathway (Taiwo et al., 1989; 
Pitchford and Levine, 1991; Taiwo and Levine, 1991; Cui and Nicol, 1995) and the Protein 
Kinase C (PKC) pathway (personal communication, V. Vellani). Therefore, in order to 
examine whether protein kinases may play a role in mediating the effect of BAM (8-22), the 
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Figure 4.6 Example plot of BAM (8-22) sensitising a previously non-responsive neurone. 
The plot is of the intracellular calcium concentration of the neurone ( as measured by F IF max) 
over time. For the duration of the time points indicated by bars the following solutions were 
added: 25 mM KCl, 100 nM capsaicin, 5 µM BAM (8-22) and 100 µM a,p-Me-ATP. 
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general kinase inhibitor staurosporine (Ruegg & Burgess, 1989; Obreja et al., 2002) was 
employed. 
Effect of BAM (8-22) in the presence of staurosporine 
200 nM staurosporine (Chen & Penington, 1996) was present throughout the experiments 
and the effect of a 4 minute application of 5 µM BAM (8-22) (grey; n=60; Figure 4.7(a)) was 
compared with control experiments (black; n=90; Figure 4.7(a)). The mean percentages (and 
the standard errors of the means) of neurones sensitised (Control= l.92±1.92%; 5 µM BAM 
(8-22) and 200 nM staurosporine=5.33±3.69%; Figure 4.7(b)) were obtained for each set of 
coverslips (Control nexp=l3; 5 µM BAM (8-22) and 200 nM staurosporine nexp=lO). These 
were not significantly different. Thus the presence of staurosporine attenuates the sensitising 
effect of BAM (8-22). 
Effect of BAM (8-22) in the presence of Ro-31-8220 
Because staurosporine is a general kinase inhibitor, other more selective kinase inhibitors 
were used in order to pinpoint the specific kinase involved. In the presence of 500 nM of the 
PKC-selective kinase inhibitor Ro-31-8220 (Davis et al., 1992), the effect of a 4 minute 
application of 5 µM BAM_ (8-22) (grey; n=I05; Figure 4.8(a)) was compared with a control 
population (black; n=90; Figure 4.8(a)). The mean percentages (and the standard errors of the 
means) of neurones sensitised (Control=l.92±1.92%; 5 µM BAM (8-22) and 500 nM Ro-31-
111 
8220=4.13±1.58%; Figure 4.8(b)) were obtained for each set of coverslips (Control nexp=l3; 1111 
5 µM BAM (8-22) and 500 nM Ro-31-8220 nexp=l3). These were not significantly different, 
and, :furthermore, in the presence ofRo-31-8220, the response was significantly different from 
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Figure 4. 7 Staurosporine does not significantly inhibit sensitisation by BAM (8-22). 
(a) A histogram displaying the percentage of neurones from control (black, n=90) and 
treatment (grey, n=60) experiments in each range of ratios comparing the size of the sixth 
capsaicin-evoked calcium transient against the size of the fifth transient (Ratio 6/5). The 
single black line plot denotes the Gaussian distribution fitted to the control data, with the 
vertical dashed lines denoting the lower 95% confidence limit (red), the mean (green), 
and the upper 95% confidence limit (blue) of this distribution. (b) A bar chart displaying the 
mean percentage of neurones with s.e.m. in control (nexp = 13) and treatment (nexp = 10) 
experiments where the value of Ratio 6/5 for the neurones is greater than the upper 95% 
confidence limit denoted in figure (a). 
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Figure 4.8 Ro-31-8220, a PKC selective inhibitor, significantly inhibits the sensitisation 
by BAM (8-22). 
(a) A histogram displaying the percentage of neurones from control (black, n=90) and 
treatment (grey, n=105) experiments in each range of ratios comparing the size of the 
sixth capsaicin-evoked calcium transient against the size of the fifth transient (Ratio 6/5). 
The single black line plot denotes the Gaussian distribution fitted to the control data, with the 
vertical dashed lines denoting the lower 95% confidence limit (red), the mean (green), and 
the upper 95% confidence limit (blue) of this distribution. (b) A bar chart displaying the mean 
percentage of neurones with s.e.m. in control (nexp=13) and treatment (nexp=13) experiments 
where the value of Ratio 6/5 is greater than the upper 95% confidence limit in figure (a). 
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BAM (8-22) alone. In addition, the ratio of the area under the transients evoked by the fifth 
and sixth capsaicin additions was calculated (AreaRatio 6/5) (Figure 4.9(a)). There was no 
significant difference at the 0.05 level between the control data (4.37±2.41%) and the BAM 
(8-22) and Ro-31-8220 data (14.14±7.67%) (Figure 4.9(b)). Thus the presence of Ro-31-
8220 attenuates the sensitising effect of BAM (8-22). 
Effect of BAM (8-22) in the presence of H-89 
In the presence of 500 nM of the PK.A-selective kinase inhibitor H-89 (Shu & Mendell, 
2001), the effect of a 4 minute application of 5 µM BAM (8-22) (grey; n=l 18; Figure 4.lO(a)) II/! 
was compared with a control population (black; n=90; Figure 4.lO(a)). The mean percentages I 
(and the standard errors · of the means) of neurones sensitised (Control= l.92±1.92%; 5 µM 
BAM (8-22) and 500 nM H-89=10.49±3.19%; Figure 4.lO(b)) were obtained for each set of 
coverslips (Control nexp=l3; 5 µM BAM (8-22) and 500 nM H-89 nexp=l3). These were not 
significantly different. In addition, the ratio of the area under the transients evoked by the 
fifth and sixth capsaicin additions was calculated (AreaRatio 6/5) (Figure 4.1 l(a)). There was 
no significant difference at the 0.05 level between the control data (4.37±2.41%) and the 
BAM (8-22) and H-89 data (13.32±4.01%) (Figure 4.1 l(b)). 
Summary of Calcium Imaging Experiments 
Figure 4.12 summarises the results obtained from the calcium imaging experiments with the 
selective SNSR agonist BAM (8-22). The application of 5 µM BAM (8-22) for 4 minutes 
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Figure 4.9 Ro-31-8220, a selective PKC inhibitor, does not significantly attenuate the 
increase in area of the capsaicin-evoked calcium transient mediated by BAM (8-22). 
(Same as figure 4.8 except that AreaRatio 6/5 is being examined) 
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Figure 4.10 H-89, a PKA selective inhibitor, does not significantly inhibit the 
sensitisation by BAM (8-22) of the response of DRG neurones to capsaicin. 
(a) A histogram displaying the percentage of neurones from control (black, n=90) and 
treatment (grey, n=l 18) experiments in each range ofratios comparing the size of the sixth 
capsaicin-evoked calcium transient against the size of the fifth transient (Ratio 6/5). The 
single black line plot denotes the Gaussian distribution fitted to the control data, with the 
vertical dashed lines denoting the lower 95% confidence limit (red), the mean (green), and the 
upper 95% confidence limit (blue) of this distribution. (b) A bar chart displaying the mean 
percentage of neurones with s.e.m. in control (nexp=13) and treatment (nexp=13) experiments 
where the value of Ratio 6/5 for the neurones is greater than the lower 95% confidence limit 
denoted in figure (a). 
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Figure 4.11 H-89, a PKA selective antagonist, does not significantly attenuate the 
increase in area of the capsaicin-evoked calcium transient mediated by BAM (8-22). 
(Same as figure 4.10 except that AreaRatio 6/5 is being examined). 
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Figure 4.12 Summary Bar Chart: BAM (8-22) sensitises the response of neurones to 
capsaicin via a mechanism involving PKC. 
Bar chart summarising the sensitisation evident from Ratio 6/5 in the experiments with 
BAM (8-22) and various protein kinase inhibitors. Each bar represents the mean percentage 
of neurones (with s.e.m.) where the value of Ratio 6/5 for the neurones is greater than the 
upper 95% confidence limit for the control data. Control (nexp=13), 5 µM BAM (8-22) 
(nexp=l9), and 5 µM BAM (8-22) with the following inhibitors: 200 nM staurosporine (ST) 
(nexp=IO), 500 nM Ro-31 -8220 (nexp=13), and 500 nM H-89 (nexp=l3). * indicates that the 
mean difference is significant at the 0.05 level when compared using a one-way analysis of 
variance with a Bonferroni post hoe test. 
between the fifth and sixth capsaicin additions results in a significant number of neurones 
being sensitised compared with control. The general kinase inhibitor staurosporine results in 
a marked, but not significant, suppression of the number of neurones sensitised. The PKC-
selective inhibitor Ro-31-8220 results in a significant suppression of the number of neurones 
sensitised by BAM (8-22), while the PK.A-selective inhibitor H-89 causes a minor, but not 
significant, suppression of the number of neurones sensitised by BAM (8-22). Therefore, it 
appears that BAM (8-22) results in a sensitisation of the response of nociceptive neurones to 
capsaicin and that this sensitisation occurs via a pathway involving PKC. 
Some further ideas of the nature of this sensitisation are given by other analysis that was 
carried out on the same data. When the AreaRatio 6/5 data was compared, BAM (8-22) may 
have increased the percentage of neurones falling above the upper 95% confidence limit, 
although the difference did not reach statistical significance. Furthermore, when Ro-31-8220 
was present there was a decrease in the mean of the percentage of neurones sensitised but the 
s.e.m. in this case was rather large. The calcium imaging technique employed may well not 
provide an accurate enough means by which to assess the involvement of TRPVI, given the 
potential involvement of voltage-dependent calcium channels, and thus the utilisation of a 
more precise technique such as patch clamping is necessary. This would permit further 
assessment of the involvement of PKC. 
Before establishing a direct involvement of TRPVI, and whether PKC is linked to 
sensitising it. The PKC isoforms involved in the sensitisation of nociceptive neurones by 
BAM (8-22) were examined. This was done by utilising an immunocytochemical assay 
which examined the translocation of various PKC isoforms. 
I I 
I 
Jmmunocytochemistry 
Activation of PKC often leads to its translocation to the membrane. In cultured neonatal rat 
sensory neurones there are 5 known isoforms of PKC: ~I, ~II, &, s, and ~ (Cesare et al., 
1999a). The isoforms ~I and ~II are already associated with the cellular membrane and so it 
is not possible to examine their activation through a translocation assay. The isoforms &, s 
and~ are not membrane-associated (Cesare et al., 1999a) and thus can be assessed using this 
assay. 
In addition to exposure to 5 µM BAM (8-22) for 4 minutes, neurones were exposed to 
DPBS only as a control treatment, and for & and s isoforms, were exposed to PMA as a known 
translocator of these isoforms of PKC. PKC- ~ is not activated by phorbol esters (Ways et al., 
1992). Figure 4.13 contains example images for the three different isoforms of PKC 
examined when the neurones had been treated with DPBS (Figure 4.13(a)), 5 µM BAM (8-
22) (Figure 4.13(b)), and 1 µM PMA (Figure 4.13(c)). In none of the control experiments 
(Figure 4.13(a)) was any clear translocation to the periphery seen. Clear translocation was 
taken to be a solid ring of red adjacent to the plasma membrane. Such a clear translocation is 
evident in Figure 4.13(c) for the PMA data. When neurones treated with BAM (8-22) were 
examined no clear translocation to the periphery was seen (Figure 4.13(b)). Such an effect is 
reflected in the overall results presented in Table 4.1. 
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Figure 4.13 Localisation of Protein Kinase C isoforms in cultured DRG neurones 
Neurones were exposed for four minutes to (a) PBS, (b) 5µM BAM (8-22) and (c) lµM 
PMA. The scale bars in the example images above represent 1 Oµm. 
Number of 
PKC Number of neurones 
Treatment neurones 
isoform displaying translocation 
analysed 
Delta (o) DPBS 183 2 
1 µMPMA(4min) 182 57 
5 µM BAM (8-22) (4 min) 362 5 
Epsilon (E) DPBS 341 2 
1 µM PMA (1 min) 134 37 
1 µMPMA(4min) 225 38 
5 µM BAM (8-22) (1 min) 445 0 
5 µM BAM (8-22) (4 min) 390 0 
Zeta(<'.;) DPBS 172 0 
5 µM BAM (8-22) (4 min) 369 0 
Table 4.1 Translocation of various PKC isoforms by PBS, PMA and BAM (8-22) 
The delta (o) isoform of PKC was seen to be significantly translocated (at the 0.01 level) by a 
4 minute treatment with 1 µM PMA compared with control data, but was not translocated 
when BAM (8-22) ~as applied. The epsilon (i::) isoform of PKC has been previously 
identified as playing a role in mediating the effect of sensitising agents on nociceptive 
neurones (Cesare et al., 1999a). The effect has been previously identified to be time 
dependent when the translocation is evoked by a receptor agonist (i.e. bradykinin) (Cesare et 
al., 1999a) and so applications lasting 1 and 4 minutes were tried. 1 µM PMA, for either 
length of time, resulted in a significant percentage of neurones showing translocation ( at the 
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Number of 
PKC Number of neurones 
Treatment neurones 
isoform displaying translocation 
analysed 
Delta (c5) DPBS 183 2 
1 µMPMA(4min) 182 57 
5 µM BAM (8-22) ( 4 min) 362 5 
Epsilon (E) DPBS 341 2 
1 µM PMA (1 min) 134 37 
1 µM PMA (4 min) 225 38 
5 µM BAM (8-22) (1 min) 445 0 
5 µM BAM (8-22) ( 4 min) 390 0 
Zeta(<'.;) DPBS 172 0 
5 µM BAM (8-22) ( 4 min) 369 0 
Table 4.1 Translocation of various PKC isoforms by PBS, PMA and BAM (8-22) 
The delta(<>) isoform of PKC was seen to be significantly translocated (at the 0.01 level) by a 
4 minute treatment with 1 µM PMA compared with control data, but was not translocated 
when BAM (8-22) w~ applied. The epsilon (E) isoform of PKC has been previously 
identified as playing a role in mediating the effect of sensitising agents on nociceptive 
neurones (Cesare et al., 1999a). The effect has been previously identified to be time 
dependent when the translocation is evoked by a receptor agonist (i.e. bradykinin) (Cesare et 
al., 1999a) and so applications lasting 1 and 4 minutes were tried. 1 µM PMA, for either 
length of time, resulted in a significant percentage of neurones showing translocation ( at the 
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0.01 level) compared with control data where negligible translocation was seen. Treatment 
with 5 µM BAM (8-22) for either length of time did not result in any translocation. The zeta 
(t.;;) isoform of PKC is not translocated by PMA and thus it was not possible to carry out a 
positive control for this isoform, however, there was no translocation with either the control 
or BAM (8-22) treatment. 
Thus none of the three isoforms of PKC examined showed any translocation by BAM 
(8-22). This may be because one of the PKC isoforms (~I and ~II) which are already 
associated with the plasma membrane is activated by BAM (8-22). Alternatively, other work 
has shown that PKC-c> can activate the non-receptor tyrosim, kinase, Src (Brandt et al., 2003). 
Src, in tum, can phosphorylate TRPVl on tyrosine residues to potentiate its activity (Jin et al., 
2004). Therefore, a possible hypothesis may be the involvement of this pathway in the 
sensitisation of TRPVl by BAM (8-22). Therefore, although BAM (8-22) did not result in 
any significant translocation of PKC-c>, it could still be acting via this isoform. Further work 
will need to be carried out to investigate this possibility. 
Conclusion 
Activation of SNSRs by the use of the selective ligand BAM (8-22) was found to sensitise 
the response of a subset of those neurones responding to capsaicin ( and thus expected to 
express TRPVl). This provides a cellular basis for the behavioural studies reported by Cao et . j 
al. (2003) and Grazzini et al. (2004) in which BAM (8-22) was found to cause heat 
hyperalgesia. The sensitisation of the amplitude of the capsaicin-evoked calcium increase 
was found to be mediated by PKC. When the isoforms were examined using an 
immunocytochemical translocation assay, none of those tested (PKC-c>, c and t.;;) were found to 
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translocate in response to treatment with BAM (8-22). Further work is necessary in this area 
in order to elucidate fully the intracellular signalling pathway that underlies the sensitisation 
by BAM (8-22). The calcium imaging technique employed, whilst permitting a large sample 
of cells to be screened, does not, necessarily, give a clear indication of the involvement of 
TRPVl because of the involvement of voltage-gated calcium channels in the generation of the 
capsaicin-evoked calcium transient ( discussed further in Chapter 6). In order to further 
elucidate the mechanism of action it was decided to investigate if BAM (8-22) directly 
sensitised TRPV 1 utilising the patch clamp method. Such an effect has been reported before 
for other sensitising agents such as PGE2, and so is a strong possibility. 
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Results: SNSRs and TRPVl 
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Introduction 
In the last chapter, it was shown that the activation of sensory neurone-specific receptors 
(SNSRs) on a subset of nociceptive neurones resulted in a sensitisation of their response to 
capsaicin. Furthermore, this sensitisation was seen to be mediated by Protein Kinase C 
(PKC). Because in the calcium imaging experiments the neurones were not under voltage 
clamp, the sensitisation of the response to capsaicin could be a result of the modification of a 
number of cellular sites involved in setting the sensitisation of neuronal excitability (e.g. 
voltage-gated ion channels). Furthermore, the fact that it was the Ratio 6/5 values ( a measure 
of the height of the evoked calcium transient and thus likely to be associated with the 
activation of voltage-gated calcium channels) that were substantially sensitised, and that the 
AreaRatio 6/5 values were sensitised in a non-significant manner, meant that further 
investigation was necessary in order to establish if a direct sensitisation of TRPVI occurred. 
In order to examine if TRPVI itself was sensitised as a result of the activation of SNSRs by 
BAM (8-22), it was decided to carry out experiments in which the membrane current 
activated by capsaicin was examined more directly under voltage clamp conditions. This was 
not tried initially given the greater experimental difficulty and the associated lower number of 
neurones assessed. 
Repeated capsaicin additions 
Cultured dorsal root ganglion (DRG) neurones were patch clamped in the whole-cell 
configuration, and held at a membrane potential of -80 m V. They were then exposed to 
100 nM capsaicin for 1 s, every 30 s. The peak inward current evoked by the capsaicin 
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applications was measured. Figure 5.l(a) shows an example plot of a control experiment and 
Figure 5.l(b) displays individual capsaicin-evoked inward currents from the fifth and eighth 
capsaicin additions. The experimental protocol provided a suitable model whereby any · 1 1 
modulation ofTRPVl could be examined. 
The effect of BAM (8-22) on TRPVJ 
To examine the effect of BAM (8-22) on TRPVI, 5µM BAM (8-22) was applied for 5 
minutes following the sixth capsaicin addition. Figure 5.2(a) shows an example plot of a 
neurone showing sensitisation by BAM (8-22) and Figure 5.2(b) displays individual 
capsaicin-evoked inward currents from the fifth and eighth capsaicin additions. Because of 
the variability in the consistency of the response of individual neurones to capsaicin there was 
some difficulty in finding an adequate means for quantatively assessing whether a neurone 
had been sensitised by the application of BAM (8-22). Figure 5.3 contains some examples of 
neurones that were not sensitised when exposed to BAM (8-22). In Figure 5.3(a) the addition 
of BAM (8-22) resulted in an initial increase in the inward current but this soon settled down 
to baseline. This initial increase is therefore likely to have been due to a movement artefact 
following the solution change and not a result of the agonist itself. Figure 5 .3(b) displays a 
neurone where the addition of BAM (8-22) had no effect at all. 
Therefore, the following method was used for analysis. When BAM (8-22) was added it 
was present from the sixth capsaicin addition until the fifteenth addition. Thus the three 
points prior to the BAM (8-22) treatment period, and all the points after, were used to fit a 
predicted baseline using linear regression. The differences between the points and this 
predicted baseline were calculated, and for each neurone 99.9% confidence limits were fitted 
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Figure 5.1 Example of a control neurone repeatedly responding to capsaicin. 
(a) Responses to 100 nM capsaicin are denoted by the points on the graph and the predicted 
baseline by the black line. (b) Individual evoked responses (filtered at lHz) to 100 nM 
capsaicin from the neurone detailed in (a). The black trace is the response at 2 minutes, and 
the grey trace is the response at 3.5 minutes. The application of capsaicin is indicated by the 
black line. 
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Figure 5.2 An example of BAM (8-22) sensitising the response of a neurone to capsaicin. 
(As for figure 5.1 with the addition of 5 µM BAM (8-22) indicated by the labelled line) 
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Figure 5.3 Examples of neurones exposed to BAM (8-22) that were found not to be 
sensitised 
Responses to 100 nM capsaicin are denot~d by the points on the graph and the application of 
BAM (8-22) is indicated by the black line. 
~ 
to this calculatetl data. Then for each neurone the confidence limits were applied to the 
differences between the predicted baseline and the points during the treatment period. Using 
a comparison of the actual traces with this analysed data it was determined that if a neurone 
had a run of significant negative differences, centred away from the edges of the treatment 
period, then it was sensitised. This analysis showed that 2 out of 17 neurones were sensitised 
by BAM (8-22). 
In addition to examining the peak inward current, the decay component of the response to 
capsaicin, as measured using a one-term, standard exponential fitted using the Simplex fitting 
method (with zero-shift), revealed in three cases a significant increase in value indicative of a 
slowed return to baseline. According to Vellani et al. (2001), longer applications of capsaicin 
result in an increased current and a longer time to return to baseline. Thus as discussed 
earlier, with PGE2, a prolonged interaction of capsaicin with TRPVl could be indicative of a 
sensitised receptor. Therefore, when this measurement is used, 3 out of the 17 cases are 
sensitised by BAM (8-22). Interestingly, only 1 of these 3 showed a significant increase in 
the peak inward current. 
In addition to examining the peak inward current, the response of each neurone to a,~-Me-
ATP was assessed in order to test for the presence of P2X3 receptors. All neurones that 
responded to capsaicin, and were able to be tested for responsiveness to a,~-Me-ATP (n=13), 
did respond. Thus all TRPV 1 expressing neurones in these experiments were also found to 
express P2X3 receptors. This is different from the calcium-unaging experiments where some 
experiments showed TRPVl expressing neurones to be non-responsive to a,~-Me-ATP. This, 
however, may be as a result of a lower n number. 
The effect of BAM (8-22) in the presence of Ro-31-8220 
Because the calcium imaging experiments from the previous chapter showed that PKC was . JJ//j 1 
involved in the sensitisation of nociceptive neurones by BAM (8-22), the effect of BAM (8-
22) on TRPVl was also examined in the presence of the PKC selective inhibitor Ro-31-8220. 
The same protocol was followed as for examining the effect of BAM (8-22) except that 
500nM Ro-31-8220 was present throughout. Figure 5.4(a) contains an example plot of a 
neurone, which although moderated by the presence of Ro-31-8220 when compared with 
Figure 5.2, was still determined to be sensitised by BAM (8-22). Figure 5.4(b) displays 
individual capsaicin-evoked inward currents from the fifth and eighth capsaicin additions. 
Again, 2 out of 17 neurones were seen to sensitise in response to the application of BAM (8-
22). 
Therefore, these experiments do not support PKC involvement in the sensitisation of 
TRPVl by BAM (8-22). The number of experiments is too small, however, to allow definite 
conclusions to be drawn. 
Comparison of cell diameter with sensitisation 
Figure 5.5 displays a comparison of cell diameter with sensitisation by BAM (8-22). The 
figure reveals that there is no cluster of neurones around a specific cell diameter, and instead 
those neurones which do sensitise appear spread across the range of cell diameters for 
neurones in these experiments. Again a greater n number would permit a more accurate 
assessment of whether particular cell diameters are sensitised. 
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Figure 5.4 An example of a neurone where the sensitising effect of BAM (8-22) is 
moderated by the presence of the PKC selective inhibitor, Ro-31-8220 (500 nM). 
(As for figure 5.2 except that Ro-31-8220 is present throughout) 
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Conclusion 
The above patch clamp experiments show that the sensitising effect of BAM (8-22) involves 
an enhancement of the response of TRPVl in a subset of nociceptive neurones. The 
percentage of neurones sensitised in this manner (12%) is similar to that seen in the calcium 
imaging experiments, but unlike in those experiments no clear evidence was found for an 
inhibition of sensitisation in the presence of the PKC inhibitor Ro-31-8220. 
There is a slight caveat associated with these data in that, in order to maximise the number 
of neurones from which recordings could be obtained, DRG neurones of a specific / / 
morphology were selected to be patched given their increased likelihood of expressing 
TRPVl (based upon previous work by Paolo Cesare). Thus the percentage reported for the 
patch clamp experiments is biased by this fact. 
Chapter 6 
Discussion 
6.1 Vanilloid receptor (TRPVl) activation by capsaicin 
Capsaicin is known to cause an increase in intracellular calcium levels in a subpopulation of 
cultured dorsal root ganglion (DRG) neurones (Dray et al., 1990; Akerman and Gronblad, 
1992; Cholewinski et al., 1993; Greffrath et al., 2001; Savidge et al., 2001) as a result of the 
activation of the TRPVl receptor (Caterina et al., 1997). The increase in intracellular calcium 
level depends on the presence of extracellular calcium (Cholewinski et al., 1993; Greffrath et 
al., 2001; Savidge et al., 2001) with the major influx being through voltage-gated calcium 
channels, as well as an approximate 25% influx through the TRPVl receptor itself (Akerman 
and Gronblad, 1992; Greffrath et al., 2001). Some reports have also suggested that the release 
of calcium from intracellular stores plays a small but significant role (Cholewinski et al., 
1993; Greffrath et al., 2001 ). The return of the intracellular calcium level to a basal level is 
carried out by mechanisms contributing to intracellular calcium homeostasis (Greffrath et al., 
2001 ). Based upon preliminary experiments and published concentration-response data 
(Cholewinski et al., 1993), 100 nM capsaicin was selected to activate the TRPVl receptors as 
it was close to the published half maximal effective concentration (EC50) value. 
In order to examine the modulation of the responsiveness of DRG neurones expressing the 
TRPVl receptor, while removing as far as possible the complicating factor of tachyphylaxis 
of the response, neurones were repeatedly exposed to 100 nM capsaicin. An inter-stimulus 
interval of four minutes was selected based upon work previously carried out in the lab by 
Jennifer Bonnington (Bonnington and McNaughton, 2003). Tachyphylaxis on repeated 
capsaicin additions (as seen in Figure 3.2) has been demonstrated before in other studies 
(Docherty et al., 1996; Koplas et al., 1997) and is believed to be as a result of the activation of 
calcineurin, by increased intracellular calcium levels, which then dephosphorylates and 
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desensitises the TRPVl receptors (Docherty et al., 1996). Once a steady response had been 
reached a clearer interpretation of the effect of a treatment could be made. 
6.2 Cannabinoid receptors 
Effect of the activation of cannabinoid receptors on nociceptive neurones 
In order to examine if the activation of cannabinoid receptors on nociceptive neurones 
affects the responsiveness of the neurones it was necessary to select a suitable cannabinoid 
receptor agonist. The synthetic cannabinoid WIN 55,212-2, known for efficacy at both CB1 
and CB2 receptors (Pertwee, 2000), was selected rather than the endocannabinoid anandamide 
(which features in many recent cannabinoid studies) because of the potential complication 
that could be introduced by its activation of TRPVl receptors (Zygmunt et al., 1999; Smart et 
al., 2000; Tognetto et al., 2001). Treatment with 100 nM WIN 55,212-2 for two minutes was 
not found to have any significant effect on the responsiveness of non-sensitised nociceptive 
neurones to capsaicin, as measured by the increase of intracellular calcium concentration. A 
significant effect following CB1 receptor stimulation, however, has been seen in previous 
studies on evoked increases in intracellular calcium levels in cultured DRG neurones 
(Tognetto et al., 2001; Millns et al., 2001) as well as on capsaicin-evoked calcitonin gene 
related peptide (CGRP) release (Ahluwalia et al., 2003). The activation of CB1 receptors on 
cultured DRG neurones was also shown by Ross et al. (2001) to cause an inhibition of 
voltage-gated calcium channels. There are several reasons the present study has not revealed 
a significant inhibition of nociceptor responsiveness following cannabinoid receptor 
activation. One of the most obvious is the nature of the analysis. When determining if a 
- 84 -
neurone had desensitised, there is a much smaller range of values that it can be in order for it 
to be classified as desensitised. Thus the analysis employed is less sensitive to . detecting 
desensitisation. Ross et al. (2001) saw a significant effect with 100 nM WIN 55,212-2 on 
voltage-gated calcium channels in DRG neurones, so it is unlikely that the concentration of 
WIN 55,212-2 was insufficient, although Ross et al. (2001) utilised a longer treatment period. 
Interestingly, Khasabova et al. (2002) did find WIN 55,212-2 to have an inhibitory effect on 
K+ -evoked increases in intracellular calcium concentration. In this case, however, the much 
higher concentration of 1 µM WIN 55,212-2 was employed. Furthermore, the neurones in 
which this effect was seen rarely responded to capsaicin. 
Much of the behavioural work discussed in the introduction has suggested that the effects of 
cannabinoid receptor activation in the periphery are antihyperalgesic rather than analgesic. 
The effect of WIN 55,212-2 on TRPVl in neurones in which the response to capsaicin had 
been potentiated by prior application of PGE2 was therefore studied. 
Effect of PGE2 on nociceptive neurones 
Exposing cultured dorsal root ganglion neurones to 1 µM PGE2 for two minutes resulted in 
both a visible sensitisation of the response of a subset of neurones to the application of 
capsaicin, and a s~nsitisation of a significant proportion of nociceptive neurones when 
compared with control data. The percentage of neurones found to be sensitised 
(approximately 21 % when the transient height was examined and 31 % when the transient area 
was examined) is slightly less than the 37% previously reported by Pitchford and Levine 
(1991). Such a sensitisation is believed to be mediated on a molecular level by the cyclic 
3',5'-adenosine monophosphate/Protein Kinase A (cAMP/PKA) modulation of the ion 
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channels involved in mediating the tetrodotoxin-resistant (TTX-R) sodium current- to 
increase their unitary current and lower the membrane potential threshold at which they 
activate (England et al., 1996; Gold et al., 1996b ). An increase in the mean channel activity 
of TRPVl has also been reported (Lopshire and Nicol, 1998). Both of these modulations 
could be expected to result in an increase in the elevation of the intracellular calcium levels 
evoked by capsaicin by making the neurone more responsive- in a general sense by the TTX-
R sodium current modulation, and specifically by enhancing the response of the TRPVl 
receptor (Caterina et al., 1997). 
The duration of the sensitisation was assessed in these experiments and was generally found 
to be limited to the capsaicin addition immediately after the treatment with PGE2. The effect 
of PGE2 was therefore rapid in onset, and also recovered from rapidly. The phenotype of the 
neurones sensitised by PGE2 in these experiments was assessed by examining responsiveness 
to a P2X3 agonist. In order to do this, the selective agonist a,~-methyleneadenosine 5'-
triphosphate (a,~-Me-ATP) was employed. In the present experiments, approximately 43% 
of neurones responded to capsaicin, and 44% of neurones responded to a,~-Me-ATP. 
Previous studies have shown that both in vitro (Wood et al., 1988) and in situ (Guo et al., 
1999) at least 50% of DRG neurones express TRPVl. Although this is very species 
dependent, the neurones in the present study are close to the expected phenotype. a,~-Me-
ATP has been shown to selectively activate P2X3 receptors in cultured neonatal rat DRG 
neurones (Robertson_ et al., 1996; Rae et al., 1998). The EC5o value for a,~-Me-ATP to evok~ 
transient, inward currents in these neurones has been shown to be approximately 2µM 
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(Robertson et al., 1996) thus the 1 OOµM employed in the present study should be more than J 1 
sufficient to activate all the P2X3 receptors present. Studies examining the percentage of 
neurones expressing P2X3 receptors do not, however, all agree. Both Grubb & Evans (1999) 
and Guo et al. (1999) indicate that approximately 80% of adult rat DRG neurones could be 
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expected to express P2X3 receptors. This contrasts with Vulchanova et al. (1997) who 
. suggested that expression is limited to 40% of neurones in rat and Chen et al. (1995) where 
approximately 56% of rat DRG neurones were found to express levels of P2X3 transcript 
above background signals. The present study, using neonatal neurones, found 44% of 
neurones which could be expected to express P2X3 receptors which is more in line with the 
results from Vulchanova et al. (1997). The explanations offered by Guo et al. (1999) for the 1 
discrepancies between their findings and Vulchanova et al. (1997), such as selective survivai I 
of smaller diameter neurones, strain differences, and functional studies providing a more 
sensitive assay for receptor expression do not hold in the present study, because as in Guo et 
al. (1999), the present study selects smaller diameter neurones, employs Wistar rats, and 
involves a functional study. The most likely source of difference is the use of neonatal rats in 
the present study. The present study found approximately 38% of TRPVl expressing 
neurones also express functional P2X3 receptors, much less than the 75% reported by Guo et 
al. (1999). When sensitisation by PGE2 was examined there did not appear to be any bias 
towards those neurones which did express P2X3. 
Approximately 10% of the neurones analysed responded to capsaicm only following 
treatment with PGE2• Such a recruitment of' silent' sensory neurones (Michaelis et al., 1996) 
has indeed been seen after PGE2 exposure before (Mense, 1981; Stucky et al., 1996) and 
could aid to promote central sensitisation at the dorsal horn (which underlies secondary 
hyperalgesia). Such recruitment could be mediated by sensitisation of the TRPVl receptor 
(Lopshire and Nicol, 1998). Also, a subsequent activation of voltage-gated calcium channels 
would be promoted by sensitisation of the TTX-R sodium current (England et al., 1996; Gold 
et al., 1996b). 
In conclusion, sensitisation was observed following treatment by PGE2• The transient 
nature of the recruitment of 'silent' neurones, and the fact that the sensitisation evoked by 
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PGE2 was seen to disappear in subsequent capsaicin additions, may suggest that calcium entry 
' 
activates phosphatases (e.g. calcineurin) which antagonise the cAMP/PKA mediated PGE2 
sensitisation. 
Possible mechanisms of antihyperalgesia 
Sensitisation of nociceptive neurones can occur via a variety of mechanisms, and thus 
antihyperalgesia can also occur via a range of mechanisms. Sensitisation can be mediated by 
ligands directly interacting with ion channels, as well as effects mediated via second 
messenger signalling cascades. As discussed in the introduction, protons can directly 
modulate the responsiveness of TRPVl. Furthermore, 5-hydroxytryptamine (5HT) (Cardenas 
et al., 2001), tumour necrosis factor a (TNFa) (Junger and Sorkin, 2000), nerve growth factor 
(NGF) (Shu and Mendell, 1999), histamine (Mizumura et al., 1994), prostaglandins (England 
et al., 1996) and bradykinin (Burgess et al., 1989) all modulate the sensitivity of nociceptors 
through intracellular signalling mechanisms. The two major signalling pathways involved in 
sensitisation are the protein kinase C (PKC) and PKA pathways. Therefore in order to have 
an antihyperalgesic effect one of three things must occur:-
(a) the agonist is sequestered from its site of action, 
(b) there is a · <;lirect attenuation of the transducer on which the sensitising effect 1s 
occurring (e.g. as when calcineurin causes the desensitisation ofTRPVl), or 
( c) there is an attenuation of the sensitising pathway itself. 
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Effect of cannabinoid receptor activation on sensitised nociceptive neurones 
Treatment with the cannabinoid receptor agonist WIN 55,212-2 at the same time as PGE2 
was not seen to significantly attenuate the sensitisation previously seen with PGE2. This may 
be as a result of either too low a concentration of cannabinoid agonist being employed or too 
short an incubation. Sensitisation by PGE2, however, is only one facet of the sensitisation that · 
can occur with nociceptive neurones. Reports from the Rice group (Farquhar-Smith et al., 
2002; Farquhar-Smith and Rice, 2003) show that the endogenous cannabinoid system can 
modulate the nerve growth factor (NGF)-mediated components of inflammatory hyperalgesia. 
Furthermore, the in vivo effects may be as a result of the modulation of non-neuronal cells 
such as an inhibition of the release of inflammatory mediators from mast cells. Alternatively, 
the effects of cannabinoid receptor activation may centre around the inhibition of voltage-
gated calcium channels as seen by Ross et al. (2001) and Khasabova et al. (2002). The 
different nature of the assay used in the present study from others employed in published 
reports could explain why no significant antinociceptive effect was seen. This suggestion is 
perhaps supported by the mild attenuation seen in the model of sensitisation using PGE2 
employed here, which may provide a more sensitive assay. The antihyperalgesic effect could 
thus be due to an inhibition of neurogenic inflammation which would not be seen in this 
experimental protocol. 
The neuronal phenotype in the present experiments was assessed and approximately 42% of 
neurones were found to respond to 100 nM capsaicin, and 36% were found to express P2X3 
receptors. A similar result was obtained when WIN 55,212-2 was absent, though the number 
of neurones responding to a,p-Me-ATP was slightly reduced. This time, however, the 
distribution of those neurones which were sensitised by PGE2 was biased towards those 
neurones which did not express P2X3 receptors. Thus it appears that the neurones that are no 
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Implications of results with respect to localisation studies 
The lack of a statistically significant effect with the cannabinoid receptor agonist in the results 
presented here could be due to the localisation of the CB1 receptors. There have been several 
reports examining the localisation of cannabinoid receptors at the peripheral and spinal level, and 
these reports have not been consistent. Furthermore, the results obtained with respect to DRG 
neurones in vitro compared with in situ differ. In general, the results obtained in vitro (Ahluwalia 
et al., 2000; Ahluwalia et al., 2002) suggest that the majority of CB1-like immunoreactivity 
identified in DRG neurones was associated with markers for nociceptive neurones. In particular, 
almost all neurones displaying TRPVl-like immunoreactivity were found to display CB1-like 
immunoreactivity (Ahluwalia et al., 2000). Such a distribution would suggest that a modulation 
of TRPVl-expressing DRG neurones by a cannabinoid agonist could be expected in vitro. The 
lack of an effect could be due to two reasons: either functionally there is no effect, or, in fact, 
these neurones do not in fact express cannabinoid receptors. The former possibility is perhaps 
suggested by the functional study carried out by Khasabova et al. (2002) where it was found that 
despite the presence of CB 1-like immunoreactivity, a cannabinoid agonist generally had no effect 
on the responsiveness of these neurones. This is in contrast to the finding by Millns et al. (2001) 
who reported that a cannabinoid agonist could attenuate the capsaicin-induced calcium response 
in DRG neurones. The latter possibility is suggested by the numerous in situ studies that have 
shown a low level of co-localisation between CB1 receptors and markers for nociceptive neurones 
(Hohmann and Herkenham, 1998). The most recent of these by Bridges et al. (2003) reported 
that only about 7% of TRPVl expressing cells were found to express CB1 mRNA. The majority 
of DRG neurones that express CB1 receptors seem to be myelinated, non-TRPVl expressing A-
( continued) , 
longer sensitised when WIN 55,212-2 is present are more likely to express P2X3 receptors. 
Such a result ties in with the localisation study by Ahluwalia et al. (2002) in which they found 
that amongst nociceptive neurones, CB1-receptor-like immunoreactivity was more likely to be 
present in the isolectin B4 (IB4) binding population which express P2X3 receptors (Julius and 
Basbaum, 2001 ). 
* 
6.3 Sensory Neurone Specific Receptors (SNSRs) 
Effect of the activation of SNSRs on nociceptive neurones 
Sensory neurone specific receptors (SNSRs) are a novel group of GPCRs that were reported 
by Lembo et al. (2002) to be found in a subset of small diameter sensory neurones. Given 
reports by Cao et al. (2003) and Grazzini et al. (2004) that SNSR activation resulted in 
enhanced pain behaviour, and given that Lembo et al. (2002) and Zylka et al. (2003) found 
colocalisation of SNSRs with TRPVI, the effect of the SNSR selective agonist BAM (8-22) 
on the response of nociceptive neurones expressing TRPVI was examined. Grazzini et al. 
(2004) found that BAM (8-22) had an EC50 of 120±15 nM at rat SNSRI, and so 5 µM BAM 
(8-22) was selected in order to ensure a supramaximal dose was present. A four minute 
application of this treatment resulted in a significant number of neurones (approximately 
15%) sensitising compared with control data. Thus a rather low percentage of TRPVI 
expressing neurones appear to express functional SNSRs. Zylka et al. (2003) showed that 
50.9±8.0% of TRPVI expressing neurones also expressed rMrgD (see Chapter I for a 
comment on the nomenclature) and that 1.1± 1.1 % expressed rMrgC. Thus there appears not 
to be a direct correlation between rMrg expression and sensitisation. There could be several 
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fibre neurones (Bridges et al., 2003). Such a result is supported by the results of Hohmann and 
Herkenham (1998), and Hohmann and Herkenham (1999b) who noted that the majority of CB 1 
mRNA expressing cells were those with fibres of larger diameter. Indeed Khasabova et al. 
(2002) noted that the activation of CB1 receptors inhibited the response of intermediate diameter 
neurones that rarely responded to capsaicin. 
Ahluwali~ et al. (2002) discussed reasons as to why different immunohistochemical studies 
gave different answers. One of the reasons for a difference may be the presence of more than one 
subtype of cannabinoid receptor in DRG neurones. 
In addition to the disparity in the phenotype of DRG neurones that express CB, receptors, the 
expression of CB1 receptors by DRG neurones is disputed by some reports. Hohmann and 
Herkenham (1999a) identified CB1 receptors in DRG neurones using radioligands. Hohmann et 
al. (1999) and Salio et al. (2002) reported the presence of cannabinoid receptors both pre- and 
post-synaptically in the spinal dorsal horn. Saiiudo-Pefia et al. (1999) also noted in tissue 
sections that CB I-like immunoreactivity was present in DRG as well as spinal cord. Farquhar-
Smith et al. (2000), however, found that whereas there was co-lamina! localisation in the dorsal 
horn with nociceptive primary afferents, there was little co-localisation at the fibre level. · The 
majority of CB1-like immunoreactivity was found on spinal interneurones suggesting that 
cannabinoids have a modulatory role at the level of the dorsal horn rather than at the level of 
primary sensory afferents. Salio et al. (2002) note that the difference may be due to a 
heterogeneity of cannabinoid binding sites in the dorsal horn. The result by Farquhar-Smith et al. 
(2000) is in contrast to the functional studies that show that cannabinoid agonists have a 
modulatory role in the periphery (Richardson et al., 1998a; Ko and Woods, 1999; Johanek et al., 
2001). 
( continued) 
reasons for this. Zylka et al. (2003) examined Sprague-Dawley adult dorsal root ganglia 
(DRG) whereas this present study utilises Wistar neonatal rats. Not only is there a possibility 
of strain variation, but also the chance of changed expression with age. The phenotype of 
nociceptive neurones is known to change over the course of the first two weeks of the life of a 
rat (Roy and Narahashi, 1992). There is also the difficulty in knowing to what extent 
BAM (8-22) activates rMrgD which is by far the most abundant receptor in TRPVl · 
expressing neurones. Grazzini et al. (2004) examined the effect of BAM (8-22) on rMrgC 
and found it to be a full agonist. BAM (8-22) has not been tested on rMrgD, but Grazzini et 
al. (2004) noted that it was inactive at rMrgA (which has the closest match to rMrgC at the 
amino acid level) at concentrations up to 1 OµM. Thus an action at rMrgD could be unlikely 
but more work in this area is obviously needed. Furthermore, Grazzini et al. (2004) found 
through the use of radioligand binding that only a single population of binding sites existed in 
the spinal cord and the periphery suggesting the lack of another BAM (8-22) binding site. If 
this is so then it seems anomalous that 15% of neurones sensitise rather than the 
approximately 1 % seen to express rMrgC. It seems that the most likely explanation is that the 
phenotype of neonatal neurones with respect to these receptors is different from adult DRG, 
with perhaps a greater percentage expressing rMrgC. 
The fact that a percentage of neurones is seen to sensitise following treatment with BAM (8-
22) fits with the in viva electrophysiology (Cao et al., 2003) and behavioural data (Grazzini et 
al., 2004) showing that the activation of rat SNSRs results in hyperalgesia. The present 
results showing that this occurs at the level of the neurone also links in with the finding by 
Grazzini et al. (2004) that the heat hyperalgesia seen in behaviour studies in response to the 
activation of rSNSRl is not secondary to inflammatory effects. 
As well as examining the effect of BAM (8-22) treatment on the height of the capsaicin-
evoked calcium transient the effect on the area of the evoked calcium transient was also 
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The lack of an effect of cannabinoid receptor activation in the model of sensitisation could also 
be as a result of the distribution of cannabinoid receptors as Hohmann et al. (1999) note the 
difference in cannabinoid receptor and mu opioid receptor distribution with respect to capsaicin 
sensitivity. Hohmann and Herkenham (1999b) noted that the difference in distribution of CB1 
and mu opioid receptors could underlie different roles. Cannabinoid receptors were found on 
fibres with a range of diameters, whereas mu opioid receptors were only expressed on thin 
diameter fibres. Such a difference in distribution could explain why the activation of mu opioid 
receptors has been seen to modulate the sensitisation mediated by PGE2 (Gold and Levine, 1996) 
whereas cannabinoid receptors were not found here to modulate this sensitisation. 
investigated as this could be expected to provide some indication of a direct involvement of 
TRPVl. There was, however, no significant difference in this parameter suggesting that the 
neuronal components affected most by the sensitisation were those involved in depolarisation 
(i.e. voltage-gated ion channels). 
Under inflammatory conditions some normally unresponsive primary afferent neurones 
become responsive to chemical stimuli (Michaelis et al., 1996; Stucky et al., 1996). This 
recruitment of 'silent' primary afferent neurones could be expected to contribute to 
inflammatory hyperalgesia. Thus the finding in the present study that treatment with BAM 
(8-22) results in the recruitment of 5.10% of 'silent' nociceptors provides another mechanism 
by which BAM (8-22) can result in the hyperalgesia reported by Cao et al. (2003) and 
Grazzini et al. (2004). 
No response to the application of BAM (8-22) itself was seen, ruling out a direct effect of 
BAM (8-22) on intracellular calcium levels. This result differs from previous reports in 
which SNSR was heterologously expressed. SNSR agonists were shown to cause a direct 
calcium release from intracellular stores in these expression systems (Lembo et al., 2002; Han 
et al., 2002; Grazzini et al., 2004). The release was not affected by pertussis toxin pre-
treatment (Lembo et al., 2002; Grazzini et al., 2004) but was completely inhibited by a PLC 
inhibitor (Han et al., 2002) thus suggesting that rSNSRl is a Gaq coupled-receptor (Grazzini 
et al., 2004). Han et al. (2002) further found that SNSR activation triggered calcium release 
from intracellular stores via an IP3-dependent mechanism resulting in a store activated influx 
of extracellular calcium. The lack of a similar finding in DRG neurones may be the result of a 
lack of sufficient receptor density to activate PLC to produce enough IP3 to release calcium. 
Given the fact that the present study shows that the sensitisation is limited to the capsaicin-
evoked calcium transient immediately after the treatment with BAM (8-22), and that 
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sensitisation of such a response is often limited by phosphatases (Docherty et al., 1996), it 
seemed prudent to investigate the involvement of protein kinases in this sensitisation. 
Involvement of protein kinases in the sensitisation mediated by BAM (8-22) 
Initially the general kinase inhibitor staurosporine was employed to test for possible protein 
kinase involvement. A concentration of 200 nM was selected based upon previously 
published work (Chen and Penington, 1996). Staurosporine was found to suppress the 
sensitisation by BAM (8-22) such that it was no longer significantly different from control. 
Thus there was evidence that protein kinases were involved in mediating the sensitisation by 
BAM (8-22). 
The effect of the PKC selective inhibitor Ro-31-8220 was next investigated. Selective 
inhibition of PKC was found to attenuate significantly the sensitisation mediated by BAM (8-
22) thus indicating an involvement of PKC in the sensitising pathway. 
There is some evidence that the PKA-selective inhibitor H-89 may slightly attenuate the 
sensitisation by BAM (8-22) but the effect does not reach significance. Therefore there is 
unlikely to be significant involvement of the cAMP/PKA pathway in mediating the effect of 
BAM (8-22). 
Given that PKC was _found to play a significant role in the mechanism of sensitisation 
caused by BAM (8-22), the isoform of PKC which may be involved was investigated. Cesare 
et al. (1999a) investigated the role of the various PKC isoforms found in DRG in the 
sensitising pathway linking the B2 receptor to TRPVI. Five isoforms were found in cultured 
neonatal rat DRG neurones: PKC- P1, Pn, 8, i::, and I;;. Olah et al. (2002) found that a culture of 
embryonic rat DRG neurones contained the isoform PKC-a too, and that it was involved in 
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the sensitisation of TRPVl. In the present study only the&, E, and~ isoforms were examined. 
None of these isoforms were seen to be translocated by treatment with BAM (8-22). 
Therefore if PKC is involved in the sensitisation, as suggested by the effects of Ro-31-8220, it 
must either be one of the untested isoforms, or because a signalling pathway was activated 
without translocation ( one such pathway is discussed in the overall conclusions below). 
Modulation of TRPVJ by BAM (8-22) 
As discussed earlier, and noted by both Greffrath et al. (2001), and Bonnington and 
McNaughton (2003), when cultured DRG neurones are stimulated with capsaicin, the 
resultant increase in intracellular calcium may be from three different sources: flow through 
TRPVl; release from intracellular stores; and influx through voltage gated calcium channels. 
Any sensitisation seen in a calcium imaging assay would therefore need to be investigated 
further in order to establish the molecular components that were sensitised. Bonnington and 
McNaughton (2003) utilised non-TRPVI neuronal depolarising agents (adenosine 
triphosphate (ATP) and KCl), as well as lidocaine to inhibit voltage-gated sodium channels, 
and thapsigargin to empty intracellular calcium stores, and they established that the 
sensitising action of NGF was directly on TRPVl and not via other indirect means. This 
technique therefore proved_ to be a simple and direct means of monitoring sensitisation of 
TRPVI by NGF, and allowed a large neuronal population to be assessed. 
Given that inflammatory mediators have been shown in the past to sensitise nociceptive 
neurones via alteration of the characteristics of TRPVI (Lopshire and Nicol, 1997), the direct 
effect of BAM (8-22) on the response of TRPVI to capsaicin was investigated by means of 
the patch clamp technique. This technique allows individual neurones to be voltage clamped 
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and the currents flowing across their membranes to be monitored. Use of the agonist, 
capsaicin, allowed the selective activation of only TRPVl ion channels, and thus the currents 
measured will be due to flow through TRPVl ion channels. The positive aspect of the patch 
clamp method is that it avoids the need for the substantial additional calcium imaging 
experiments reported in Bonnington and McNaughton (2003). The negative, discussed later, 
is the lower n number that can be generated within a reasonable time frame. 
Based upon the criteria for peak current ( discussed in Chapter 5) used to record if a neurone 
had been sensitised, 2 out of 17 of the neurones examined were found to be sensitised 
(compared with none in control experiments). This represents approximately 12% of 
neurones being sensitised which is not dissimilar from the percentage found by the calcium 
imaging technique. Obviously, because of limitations with data collection, the n number is 
lower than desirable for an accurate reading of the percentage of neurones that sensitise. 
The effect of selectively inhibiting PKC was also investigated using the patch clamp 
technique, but was not seen to have any effect. Further experiments or the use of different 
techniques are necessary to confinn this, as the n number is rather small. 
Phenotype of neurones sensitising to BAM (8-22) 
The neuronal phenotype _ of the neurones present in the culture of dorsal root ganglion 
neurones was also investigated. Overall in these cultures approximately 49% of neurones 
were seen to respond to 100 nM capsaicin which is as expected based on a previous study 
(Wood et al., 1988). Approximately 56% of neurones were found to respond to the P2X3 
selective agonist a,~-Me-ATP. This correlates well with the approximately 56% of DRG 
neurones that Chen et al. (1995) found to express levels of P2X3 transcript above background 
signals. Those_ neurones being responsive to a,~-Me-ATP, and thus likely to express P2X3, 
predominated in the experiments in which a sensitising effect of BAM (8-22) was seen. Such 
a finding correlates with the finding by Zylka et al. (2003) that in the rat all Mrg positive 
neurones express the purinergic receptor P2X3• The lack of complete correlation may be due 
to animal age, differences between in vivo and in vitro conditions, and rat strain. 
The nature of the neurones sensitised was also assessed in the patch clamp experiments by 
comparing cell diameter with whether or not the neurone was sensitised or not. Ueno et al. 
(1999), in a study of responses to A TP, classified their cells as: small cells, less than 25 µm in 
diameter; medium cells, between 25 and 35 µm; and large cells, greater than 35 µm. The 
neurones seen to be sensitised in the present study were split between small and medium sized 
cells, both of which could be expected to respond to a,~-Me-ATP (Ueno et al., 1999). This is 
in line with the expression pattern of nociceptive markers expected to be shown by neurones 
expressing SNSRs. 
Summary 
The activation of SNSRs on cultured nociceptive neurones by the selective agonist 
BAM (8-22) has been shown to sensitise a subset of these neurones. This sensitisation is 
predominantly in nociceptive neurones expressing the P2X3 receptor. The molecular 
mechanisms underlying the _sensitisation have only partially been elucidated, but BAM (8-22) 
has been shown here to sensitise neurones via a pathway involving PKC. 
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6.4 Overall Conclusions 
The present study furthers our knowledge of the intracellular pathways involved in the 
sensitisation of nociceptive neurones. In the cannabinoid study, the lack of effect of 
cannabinoid receptor activation on the sensitisation of the nociceptive neurones by PGE2 
suggests that the antihyperalgesic effects of cannabinoid receptor activation that are observed 
in viva are due to an alternative intracellular pathway than the hypothesised modulation of 
cAMP/PKA. Furthermore, the lack of an effect in the PGE2 model of sensitisation suggests 
that PKC-s translocation (personal communication, V. Vellani) is not involved either. 
Reports from the Rice group (Farqu.lJ.ar-Smith et al., 2002; Farquhar-Smith and Rice, 2003) 
show that the endogenous cannabinoid system can modulate the NGF-mediated components 
of inflammatory hyperalgesia. Moreover, CB2 receptor activation by palmitoylethanolamide 
(PEA) was seen to reduce NGF-mediated neutrophil influx which could be linked to thermal 1 
hyperalgesia. In comparison, CB1 receptor activation by anandamide resulted in a direct 
neuronal antihyperalgesic action in the case of the NGF induced thermal hyperalgesia. 
Farquhar-Smith and Rice (2003) conclude that this suggests a therapeutic site of analgesic 
action separable from central side effects. 
When the SNSR study is examined, PKC is seen to be involved in the sensitisation by BAM 
(8-22) of those neurones expressing TRPVl. No translocation of the PKC isoforms examined 
(&,sand 1;;) was seen in response to BAM (8-22) application. Two possibilities exist for this 
(personal communication X. Zhang): the isoforms ~1 and ~n may be involved, and as they are 
already translocated they cannot be examined in this assay, or the PKC & isoform may be 
involved in a signalling pathway where no translocation is necessary. Such a pathway is 
discussed below. Further investigation into the intracellular signalling pathways is necessary 
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in order to provide a clearer idea. For example, at which signalling point does cannabinoid 
receptor activation block the NGF sensitisation? 
The 'silent' nociceptors mentioned in the course of this study need further work to establish 
if they are really silent. For example, the responses may have been just below the threshold 
for measurement of the calcium transient height. A greater capsaicin concentration would 
ensure all those neurones which could respond prior to sensitisation, did. 
One manner in which the signalling pathways could be investigated would be to transfect 
plasmids of the cannabinoid receptors into a heterologous cell line lacking PKC-5 (such as 
those used by Brandt et al. (2003)). This would allow the involvement of PKC-5 to be 
investigated even if it does not translocate in response to activation. In fact, Brandt et al. 
(2003) found that PKC-5 via protein tyrosine phosphatase (PTP) alpha resulted in the 
activation of the non-receptor tyrosine kinase, Src. A more recent study by Jin et al. (2004) 
revealed that TRPVl is a potential target for cellular tyrosine . kinase-dependent 
phosphorylation and this includes Src. Further work to examine if NGF sensitisation is 
mediated via Src is necessary. Another manner in which the involvement of non-
translocating PKC isoforms could be examined, would be to attenuate isoform expression in 
DRG neurones e.g. by agonist-induced downregulation as in Olah et al. (2002). This could be 
used both with respect to cannabinoid receptors and SNSRs. 
Further experiments would include utilising a phospholipase C (PLC) inhibitor to confirm if 
the native rSNSRl is a Gag-coupled receptor giving rise to diacylglycerol on activation. This 
would also allow the examination of whether a decrease in phosphatidyl inositol 4,5-
bisphosphate (PIP2) through PLC-mediated hydrolysis played a role in the sensitising effect of 
BAM (8-22). This could be the case given that Chuang et al. (2001) found that a reduction of 
PIP2 levels through PLC-mediated hydrolysis could mimic the potentiating effects of 
bradykinin and NGF at the cellular level with respect to TRPVl. Given that nociceptive 
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neurones can also be sensitised via a modulation of the TTX-R sodium current, and this can 
be via the PKC signalling pathway (Gold et al., 1998), it would be worthwhile examining if 
BAM (8-22) results in the sensitisation of the TTX-R sodium current. The level of expression 
of rat SNSR in Wistar neonatal neurones could be examined to investigate if there is a 
correlation with the percentage of neurones being sensitised. Finally, a fuller 
pharmacological investigation of the activation of the SNSRs to provide an EC5o for BAM (8-
22) at the in situ receptor, as well as examining other SNSR agonists such as y2-MSH 
(Grazzini et al., 2004), would provide useful information. Of course, in a pharmaceutical 
context, the development of a selective antagonist would have potential therapeutic use. 
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